{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "1bdedf60",
   "metadata": {},
   "source": [
    "## `process_records(csv_file, FILE_NAME)`\n",
    "\n",
    "### Description:\n",
    "This function processes records from a CSV file and extracts parameter values.\n",
    "\n",
    "### Parameters:\n",
    "- `csv_file` (str): Path to the CSV file.\n",
    "- `FILE_NAME` (str): Identifier for the processed file.\n",
    "\n",
    "### Returns:\n",
    "None\n",
    "\n",
    "### Working:\n",
    "\n",
    "1. **Read CSV File**:\n",
    "   - Read the CSV file into a DataFrame.\n",
    "\n",
    "2. **Replace Values**:\n",
    "   - Replace 'token' column values with 'Abbreviation' values where 'Abbreviation' is not NaN.\n",
    "\n",
    "3. **Load JSON Data**:\n",
    "   - Load JSON data from 'X1.json' and extract values of 'Abbreviation'.\n",
    "\n",
    "4. **Concatenate Tokens**:\n",
    "   - Concatenate 'token' column values into a single string.\n",
    "\n",
    "5. **Define Regex Pattern**:\n",
    "   - Define a regex pattern for finding abbreviation matches.\n",
    "\n",
    "6. **Tokenization**:\n",
    "   - Tokenize the original text based on the regex pattern.\n",
    "\n",
    "7. **Combine Tokens**:\n",
    "   - Combine consecutive tokens into phrases until an abbreviation is encountered.\n",
    "\n",
    "8. **Extract Parameter Values**:\n",
    "   - Extract parameter values from combined tokens based on specific conditions.\n",
    "\n",
    "9. **Write Results to Text File**:\n",
    "   - Write the extracted results to a text file named 'result_{FILE_NAME}.txt'.\n",
    "\n",
    "### Example:\n",
    "```python\n",
    "process_records('data.csv', 'data')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "98ec90de",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processing file: ./files/data_02b832e1-66cc-4f35-8b52-abf41cd821b2.csv\n",
      "Concatenated strings: Patient Name ee Barcode ; [ eennnennninittte Age : Gender : 64 / Female Sample Collected On : 03 / Mar/2022 07:16AM Order I2 d : 483940780 Sample Received On : 03 / Mar/2022 11:54AM Referred By : Self Report Generated On : 03 / Mar/2022 12:57PM Customer Since : 03 / Mar/2022 Sample Temperature : Maintained Y Sample Type : Whole Blood EDTA Report Status : Final Report DEPARTMENT OF BIOCHEMISTRY HBAIC Test Name Value Unit Bio . Ref Interval HbAlIc - Glycated Hemoglobin Hbalc ( Glycosylated Hemoglobin ) | 10.50 % 4.2 - 5.7 Method : HPLC Average Estimated Glucose - plasma 254.65 mg / dt Method : Calculated INTERPRETATION : AS PER AMERICAN DIABETES ASSOCIATION ( ADA ): + REFERENCE GROUP GLYCOSYLATED HEMOGLOBIN ( HBA‘Cc ) in % Non diabetic < 5.7 At Risk ( Prediabetes ) 5.7 -6.4 Diagnosing Diabetes > = 6.5 Age > 19 Years Goals of Therapy : < 7.0 Actions Suggested : > 8.0 Therapeutic goals for glycemic control Age < 19 Years | Goal of thera REMARKS 1 . HBA1C is used for monitoring diabetic control . It reflects the mean plasma GLUC over three months 2 . HbAic may be falsely low in diabetics with hemolytic disease . In these individuals a plasma FRUCT level may be used which evaluates diabetes over 15 days . 3 . Inappropriately low HBA1C values may be reported due to hemolysis , recent blood transfusion , acute blood loss , hypertriglyceridemia , chronic liver disease . Drugs like dapsone , ribavinn , antiretroviral drugs , trimethoprim , may also cause interference with estimation of HBA1C , causing falsely low values . 4 . HBA1C may be increased in patients with polycythemia or post - splenectomy . 5 . Inappropriately higher values of HBA1C may be caused due to iron deficiency , vitamin vitB12 deficiency , alcohol intake , uremia , hyperbilirubinemia and large doses of aspirin . - 6 . Trends in HBA1C are a better indicator of diabetic control than a solitary test . 7 . Any sample with > 15 % HBA1C should be suspected of having a HGB vanant , especially in a non - diabetic patient . Similarly , below 4 % should prompt additional studies to determine the possible presence of variant HGB . 8 . HbA 1c target in pregnancy is to attain level < 6 % . 9 . HbA‘1c target in paediatric age group is to attain level < 7.5 % . Method : lon - exchange high - performance liquid chromatography ( HPLC ) . Reference : American Diabetes Associations . Standards of Medical Care in Diabetes 2015\n",
      "Regex pattern: (\\b(?:11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|Al|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|As|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|Br-|CRP|Cd2+|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|Cl-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|Cu2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|hs-cTnI|HIST|HCYS|IGC|IGC%|IPF|IRF|igA|igD|igE|igG|igM|BILIIN|IGF1|I2|Fe3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|Pb2+|LEP|LAP|LPSE|LPPA|Li+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|Mg2+|Mn2+|MCH|MCHC|MCV|MPV|MELAT|Hg2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCs|OXYT|PCPP|PTH|pCO2|pO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-He|RETI|RR%|SRNE|Na+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|vitA|vitB1|vitB12|vitB2|vitB3|vitB5|vitB6|vitB9|vitC|vitD|vitE|vitK1|WBC|Zn2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAb|TgAb|11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|AL|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|AS|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|BR-|CRP|CD2+|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CL-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|CU2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|HS-CTNI|HIST|HCYS|IGC|IGC%|IPF|IRF|IGA|IGD|IGE|IGG|IGM|BILIIN|IGF1|I2|FE3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|PB2+|LEP|LAP|LPSE|LPPA|LI+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|MG2+|MN2+|MCH|MCHC|MCV|MPV|MELAT|HG2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCS|OXYT|PCPP|PTH|PCO2|PO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-HE|RETI|RR%|SRNE|NA+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|VITA|VITB1|VITB12|VITB2|VITB3|VITB5|VITB6|VITB9|VITC|VITD|VITE|VITK1|WBC|ZN2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAB|TGAB)\\b)[\\s,:.]+\n",
      "Tokens: ['Patient Name ee Barcode ; [ eennnennninittte Age : Gender : 64 / Female Sample Collected On : 03 / Mar/2022 07:16AM Order', 'I2', 'd : 483940780 Sample Received On : 03 / Mar/2022 11:54AM Referred By : Self Report Generated On : 03 / Mar/2022 12:57PM Customer Since : 03 / Mar/2022 Sample Temperature : Maintained Y Sample Type : Whole Blood EDTA Report Status : Final Report DEPARTMENT OF BIOCHEMISTRY HBAIC Test Name Value Unit Bio . Ref Interval HbAlIc - Glycated Hemoglobin Hbalc ( Glycosylated Hemoglobin ) | 10.50 % 4.2 - 5.7 Method : HPLC Average Estimated Glucose - plasma 254.65 mg / dt Method : Calculated INTERPRETATION :', 'AS', 'PER AMERICAN DIABETES ASSOCIATION ( ADA ): + REFERENCE GROUP GLYCOSYLATED HEMOGLOBIN ( HBA‘Cc ) in % Non diabetic < 5.7 At Risk ( Prediabetes ) 5.7 -6.4 Diagnosing Diabetes > = 6.5 Age > 19 Years Goals of Therapy : < 7.0 Actions Suggested : > 8.0 Therapeutic goals for glycemic control Age < 19 Years | Goal of thera REMARKS 1 .', 'HBA1C', 'is used for monitoring diabetic control . It reflects the mean plasma', 'GLUC', 'over three months 2 . HbAic may be falsely low in diabetics with hemolytic disease . In these individuals a plasma', 'FRUCT', 'level may be used which evaluates diabetes over 15 days . 3 . Inappropriately low', 'HBA1C', 'values may be reported due to hemolysis , recent blood transfusion , acute blood loss , hypertriglyceridemia , chronic liver disease . Drugs like dapsone , ribavinn , antiretroviral drugs , trimethoprim , may also cause interference with estimation of', 'HBA1C', 'causing falsely low values . 4 .', 'HBA1C', 'may be increased in patients with polycythemia or post - splenectomy . 5 . Inappropriately higher values of', 'HBA1C', 'may be caused due to iron deficiency , vitamin', 'vitB12', 'deficiency , alcohol intake , uremia , hyperbilirubinemia and large doses of aspirin . - 6 . Trends in', 'HBA1C', 'are a better indicator of diabetic control than a solitary test . 7 . Any sample with > 15 %', 'HBA1C', 'should be suspected of having a', 'HGB', 'vanant , especially in a non - diabetic patient . Similarly , below 4 % should prompt additional studies to determine the possible presence of variant', 'HGB', '8 . HbA 1c target in pregnancy is to attain level < 6 % . 9 . HbA‘1c target in paediatric age group is to attain level < 7.5 % . Method : lon - exchange high - performance liquid chromatography ( HPLC ) . Reference : American Diabetes Associations . Standards of Medical Care in Diabetes 2015']\n",
      "Combined tokens: ['Patient Name ee Barcode ; [ eennnennninittte Age : Gender : 64 / Female Sample Collected On : 03 / Mar/2022 07:16AM Order', 'I2 d : 483940780 Sample Received On : 03 / Mar/2022 11:54AM Referred By : Self Report Generated On : 03 / Mar/2022 12:57PM Customer Since : 03 / Mar/2022 Sample Temperature : Maintained Y Sample Type : Whole Blood EDTA Report Status : Final Report DEPARTMENT OF BIOCHEMISTRY HBAIC Test Name Value Unit Bio . Ref Interval HbAlIc - Glycated Hemoglobin Hbalc ( Glycosylated Hemoglobin ) | 10.50 % 4.2 - 5.7 Method : HPLC Average Estimated Glucose - plasma 254.65 mg / dt Method : Calculated INTERPRETATION : AS PER AMERICAN DIABETES ASSOCIATION ( ADA ): + REFERENCE GROUP GLYCOSYLATED HEMOGLOBIN ( HBA‘Cc ) in % Non diabetic < 5.7 At Risk ( Prediabetes ) 5.7 -6.4 Diagnosing Diabetes > = 6.5 Age > 19 Years Goals of Therapy : < 7.0 Actions Suggested : > 8.0 Therapeutic goals for glycemic control Age < 19 Years | Goal of thera REMARKS 1 .', 'HBA1C is used for monitoring diabetic control . It reflects the mean plasma', 'GLUC over three months 2 . HbAic may be falsely low in diabetics with hemolytic disease . In these individuals a plasma', 'FRUCT level may be used which evaluates diabetes over 15 days . 3 . Inappropriately low', 'HBA1C values may be reported due to hemolysis , recent blood transfusion , acute blood loss , hypertriglyceridemia , chronic liver disease . Drugs like dapsone , ribavinn , antiretroviral drugs , trimethoprim , may also cause interference with estimation of', 'HBA1C causing falsely low values . 4 .', 'HBA1C may be increased in patients with polycythemia or post - splenectomy . 5 . Inappropriately higher values of', 'HBA1C may be caused due to iron deficiency , vitamin', 'vitB12 deficiency , alcohol intake , uremia , hyperbilirubinemia and large doses of aspirin . - 6 . Trends in', 'HBA1C are a better indicator of diabetic control than a solitary test . 7 . Any sample with > 15 %', 'HBA1C should be suspected of having a', 'HGB vanant , especially in a non - diabetic patient . Similarly , below 4 % should prompt additional studies to determine the possible presence of variant', 'HGB 8 . HbA 1c target in pregnancy is to attain level < 6 % . 9 . HbA‘1c target in paediatric age group is to attain level < 7.5 % . Method : lon - exchange high - performance liquid chromatography ( HPLC ) . Reference : American Diabetes Associations . Standards of Medical Care in Diabetes 2015']\n",
      "Extracted results: [{'parameter': 'I2', 'value': '254.65', 'unit': 'mg'}]\n",
      "Processing file: ./files/data_0ecb52fd-138f-4566-bdef-06fabdd7019d.csv\n",
      "Concatenated strings: Peghy « Ao ¢4 AG +48 | 38 — > CLINICAL LABORATORIE Page HH1 lj * I2 , mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria HAEMATOLOGY SPECIMEN : WHOLE BLOOD Date : 05/02/24 07/12/22 10/06/21 ( # Refers to current Coll . Time : 08:45 08:30 09:00 result only ) Lab Number : HAEMOGLOEIN 138 133 126 ( 115 - 165 ) g / L RBC 5.02 4.77 4.48 ( 3.80 - 5.50)x10l4 / L HCT QO.45 0.43 O.41 ( 0.35 - 0.47 ) MCV 90 91 91 ( 80 - 99 ) CL MCHC 27.5 27.9 28.1 ( 27.0 - 34.0)pgq MCHC * 305 * 306 * 309 ( 310 - 360 ) g / L RDW 14.1 12.8 12.9 ( 11.0 - 15.0)% wee 6.8 7.4 6.5 ( 4.0 - 11.0 } x107 / L NEUT 2.4 3.8 2.7 ( 2.0 - 8.0 ) x“107 / L Lymphocytea 3.6 3.0 3.0 ( 1.0 - 4.0 ) x107 / L Monocytea 0.5 0.4 0.4 ( < 1.1 ) x107 / L EOS 0.3 O.1 0.3 ( « 0.7 ) x107 / L BASO < 0.1 0.0 < 0.1 ( fe 0.3 ) * x107 / L PLATELETS 308 336 200 ( 150 - 450 ) x107 / L ESR 5 13 ( < 21 ) mm /h # 86820229 : Persistent red cell hypochromia . Serum ferritin is pending . I2 1ron atores are normal consider thalasdaemia screen . ESR is normal . CRP - R , GLS - R , GHB - R , OHD - R , RAS - W , vitB12 - R , ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 1 of 7 REMOVED Peghy « Ao ¢4 AG +48 52 — > CLINICAL LABORATORIE Page HHZ lj * I2 , mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria GENERAL CHEMISTEY SPECIMEN : SERUM Date : 05/02/24 07/12/22 10/06/21 Coll . Time : QO8:45 08:30 09:00 Lab Number : Na+ 139 139 138 ( 135 - 145 } mmol /L K+ 4.2 4.1 4.5 ( 3.5 - 5.2 } mmol /L Chloride 101 104 105 ( 95 - 110 ) mmol /L CO2 27 25 24 ( BB - 323 } mmol /L UREA 6.0 5.8 4.2 ( 3.5 - 8.0 } mmol /L CREAN 54 52 45 ( 45 - 90 } umol /L EGFR > 90 > 90 > 90 ( > 59 ) mL / min/1.73m2 T.Protein 65 67 68 ( 60 - 80 } g / L Albumin 38 35 37 ( 35 - 50 ) g / L Globulin 27 32 31 ( 23 - 39 ) g / L ALP a7 B7 68 ( 30 - 110 ) U / L Bilirubin 9 7 7 ( 3 - 30 ) umol /L GGT 16 12 14 ( 5 - 35 ) U / L AST 13 15 * 41 ( 5 - 30 ) U / L ALT zal 17 15 ( 5 - 35 ) U / L 86820229 Within reference intervals . Please note : from 09.11.23 new reference intervals apply for Liver Funetion Tests . These are sourced from the RCPA Harmonised Reference Intervals ( v2.0 ) document . CRP - R , GLS - R , GHB - R , OHD - R , RAS - W , vitB12 - R , ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 2 of 7 REMOVED Peghy « Ao G4 AG +49 : 6 — > CLINICAL LABORATOURIE Page HHS lj * I2 , mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BIOCHEMISTRY C REACTIVE FPROTEIN ( CRP ) SPECIMEN : SHRUM REMOVED In the setting of infection , CRP levels +100 mg / L are supportive of bacterial rather than viral aetiology . Note resulta from this CRP aasay should not be used for cardiac risk agssedament . Please request the high sensitivity assay ( hsCRP ) inatead . BIOCHEMISTRY GLUCOSE Date Time Lab # Collection Type Specimen Glucose ( mmol / L ) 95/02/24 08:45 618202xxx29 Fasting serum * # 1.7 12351282555529 Elevated fasting GLUC and HbAlc are consistent with diabetes . Suggest annual monitoring with urine ALB to detect diabetic nephropathy . Glucose Reference Ranges Random 3.0 - 6.9 mmol / L Fasting 3.0 - 5.4 mmol / L 1 Hour post prandial 3.0 - 11.0 mmol / L 2 Hour post prandial 3.0 - 7.7 mmol / L Specimen Legend : Fl - ox = Fluoride oxalate , serum = Serum , np = Non - Preserved CRP - R , GLS - R , GHB - R , OHD - R , RAS - W , vitB12 - R , ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 3 of 7 REMOVED Feghy « Ao G4 yAG +4921 — > CLINICAL LABORATURIE Page HH4 li * I2 Anica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BLOCHEMISTRY HAEMOGLOBIN Alc SPECIMEN : WHOLE BLOOD ITFCC DCCT Date Coll Time Req . No . HbAle ( mmol / mol ) HbAlca ( % } 05/03/24 08:45 86820229 BR ? KK 7.4 07/12/22 08:30 72256123 BS KK 7.5 BE6820229 RECOMMENDATIONS Consider review of diabetes management , if appropriate . Suggest repeat HbAle in 3 months . Note that urine microalbumin is now due . INTERPRETATION CRITERIA DIAGNOSIS . A HbAle greater than or equal to 48 mmol / mol ( 6.5 ¥ % ) 18 conalatent With diabetes . Consider OGTT or repeat HbAlec for confirmation . HbAlec 6.0 - 6.4 % 18 consistent with prediabetes . Repeat testing annuall 18 recommended . ( ADS position atatement 2020 ) MONITORING . The Australian Diabetes Society ( ADS ) recommenda individualised HbAlc targeta depending on the patient 's age , comorbidities and any Hypoglycaemia ( ADS position statement 2009 ) . A general target of less than or equal to 53 mmol / mol ( 7.0 % ) is often used . Please note that HGB Alec resulta may be influenced by conditiong affecting red cells or their survival times such as haemoglobinopathies anaemias , recent transfusion or blood loss . HbAle tested on Roche ¢513 using Gen. 3 assay . CRP - R , GLS - R , GHB - R , OHD - R , RAS - W , vitB12 - R , ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 4 of 7 REMOVED Peghy « Ao G4 AG +49 « 38 — > CLINICAL LABORATORIE Page HHS lj * I2 , mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BIOCHEMISTRY LIPID STUDIES SPECIMEN : SERUM Date : 05/02/24 07/12/22 10/06/21 Coll . Time : 08:45 08:30 09:00 Desirable Range Lab Number : Faating Status Fasting Faating Fasting Total Chol . * 6.0 * 6.23 * 6.2 ( « 5.6 ) mmol / HDL Chel . * 1.1 1.1 * 1.0 ( > 1.1 ) mmol / LDL Chel . * 3.7 * 3.9 * 4,3 ( x 3.1 ) mmol / Non - HDL Chel . * 4.9 * 5.1 * 5.2 ( x 4.1 ) mmol / Triglyceride * 2.6 * 2.7 = * 2.0 ( < 2.1 ) mmol / LDL / HDL Ratio 3.4 3.6 4.3 Chol / HDL Ratio 5.4 5.6 6.2 86820229 History of Diabetes . Interpret in conjunction with other cardiovascular risk factors or treatment targeta . Recommended targeta for high riak patients are Total cholesterol < « 4.0 mmol / L HDL Cholesterol > 1.0 mmol / L LDL Cholesterol = < 2.5 mmol / L ( < 1.8 mmol / L for very high risk ) Non - HDL Cholesterol “ = 3.3 mmol / L ( < « 2.5 mmol / L for very high risk ) Fasting triglycerides < 2.0 mmol / L Lipid ranges and targets are from the AACB Guideline for Harmonised Lipi Reporting ( 2018 ) Target values need to be individualised based on clinical assesament of overall risk . See the AusCVD Risk calculator at www.cvdcheck.org.au CRP - R , GLS - R , GHB - R , OHD - R , RAS - W , vitB12 - R , ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 5 of 7 REMOVED Peghy « Ao G4 AG +49 554 — > CLINICAL LABORATORIE Page HHo lj * I2 , mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BIOCHEMISTRY LRON STUDIES SPECIMEN : SHRUM Date : 05/02/24 10/06/21 Coll . Time : O8:45 09:00 Lab Number : Tron 14.6 * 8.7 ( 10.0 - 30.0 ) umol/ TFER 2.64 2.56 ( 2.10 - 3.80 ) g / L Saturation 22 * 14 ( 15 - 45 } % FERR * 26 * 28 ( 30 - 300 ) ug /L 86820229 Fe3+ studies are consistent with iron deficiency . BIOCHEMISTRY VITAMIN Bl2 AND FOLATE SPECIMEN : SERUM / BLOOD Date : 05/02/24 10/06/21 Time : 08:45 09:00 Lab Number : Vitamin vitB12 412 526 pmol / L vitB9 > 54.5 nmol / L 86820229 Normal Bl2 result . RANGES Biz Serum vitB9 Red Cell vitB9 Normal > 180 > 10.90 > 450 Equivocal 150 - 180 8.0 - 10.0 350 - 450 Deficient « 150 - « 5.0 « 350 Vitamin Bl2 and vitB9 analyses are performed on the Siemena Centaur/ Atellica . CRP - R , GLS - R , GHB - R , OHD - R , RAS - W , vitB12 - R , ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 6 of 7 REMOVED Peabo 64 AG : 58 + BB — > CLINICAL LABORATURIE Page HH ? lj * I2 , mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria ENDOCRINOLOGY THYROID FUNCTION TEST SPECIMEN : SERUM Date : 05/02/24 07/12/22 10/06/21 Coll . Time : 08:45 08:30 09:00 Lab Number : TSH 2.37 2.31 2.30 ( 0.40 - 4,.00)mIU / L 868202295 Normal TSH level . BLOCHEMISTRY VITAMIN D SPECIMEN : SEHEREUM 25 - hydroxy REMOVED 86820229 Within normal limita . Interpretation : Vitamin D deficiency < 50 nmol / L Severe deficiency < 20 nmol / L COMMENT : Vitamin D sufficiency is defined as greater than or equal to 50 nmol / L at the end of winter ( level may need to be 10 - 20 nmol / L highe at the end of gummer ) . Reference : Position Statement . Vitamin D and Health in Adults in Australia and New Zealand . MJA,196(11 ): 686 - 687 , 2012 . CRP - R , GLS - R , GHB - R , OHD - R , RAS - W , vitB12 - R , ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 7 of 7 REMOVED\n",
      "Regex pattern: (\\b(?:11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|Al|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|As|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|Br-|CRP|Cd2+|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|Cl-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|Cu2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|hs-cTnI|HIST|HCYS|IGC|IGC%|IPF|IRF|igA|igD|igE|igG|igM|BILIIN|IGF1|I2|Fe3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|Pb2+|LEP|LAP|LPSE|LPPA|Li+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|Mg2+|Mn2+|MCH|MCHC|MCV|MPV|MELAT|Hg2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCs|OXYT|PCPP|PTH|pCO2|pO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-He|RETI|RR%|SRNE|Na+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|vitA|vitB1|vitB12|vitB2|vitB3|vitB5|vitB6|vitB9|vitC|vitD|vitE|vitK1|WBC|Zn2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAb|TgAb|11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|AL|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|AS|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|BR-|CRP|CD2+|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CL-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|CU2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|HS-CTNI|HIST|HCYS|IGC|IGC%|IPF|IRF|IGA|IGD|IGE|IGG|IGM|BILIIN|IGF1|I2|FE3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|PB2+|LEP|LAP|LPSE|LPPA|LI+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|MG2+|MN2+|MCH|MCHC|MCV|MPV|MELAT|HG2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCS|OXYT|PCPP|PTH|PCO2|PO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-HE|RETI|RR%|SRNE|NA+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|VITA|VITB1|VITB12|VITB2|VITB3|VITB5|VITB6|VITB9|VITC|VITD|VITE|VITK1|WBC|ZN2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAB|TGAB)\\b)[\\s,:.]+\n",
      "Tokens: ['Peghy « Ao ¢4 AG +48 | 38 — > CLINICAL LABORATORIE Page HH1 lj *', 'I2', 'mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria HAEMATOLOGY SPECIMEN : WHOLE BLOOD Date : 05/02/24 07/12/22 10/06/21 ( # Refers to current Coll . Time : 08:45 08:30 09:00 result only ) Lab Number : HAEMOGLOEIN 138 133 126 ( 115 - 165 ) g / L', 'RBC', '5.02 4.77 4.48 ( 3.80 - 5.50)x10l4 / L', 'HCT', 'QO.45 0.43 O.41 ( 0.35 - 0.47 )', 'MCV', '90 91 91 ( 80 - 99 ) CL', 'MCHC', '27.5 27.9 28.1 ( 27.0 - 34.0)pgq', 'MCHC', '* 305 * 306 * 309 ( 310 - 360 ) g / L', 'RDW', '14.1 12.8 12.9 ( 11.0 - 15.0)% wee 6.8 7.4 6.5 ( 4.0 - 11.0 } x107 / L', 'NEUT', '2.4 3.8 2.7 ( 2.0 - 8.0 ) x“107 / L Lymphocytea 3.6 3.0 3.0 ( 1.0 - 4.0 ) x107 / L Monocytea 0.5 0.4 0.4 ( < 1.1 ) x107 / L', 'EOS', '0.3 O.1 0.3 ( « 0.7 ) x107 / L', 'BASO', '< 0.1 0.0 < 0.1 ( fe 0.3 ) * x107 / L PLATELETS 308 336 200 ( 150 - 450 ) x107 / L', 'ESR', '5 13 ( < 21 ) mm /h # 86820229 : Persistent red cell hypochromia . Serum ferritin is pending .', 'I2', '1ron atores are normal consider thalasdaemia screen .', 'ESR', 'is normal .', 'CRP', '- R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12', '- R ,', 'ESR', '- R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 1 of 7 REMOVED Peghy « Ao ¢4 AG +48 52 — > CLINICAL LABORATORIE Page HHZ lj *', 'I2', 'mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria GENERAL CHEMISTEY SPECIMEN : SERUM Date : 05/02/24 07/12/22 10/06/21 Coll . Time : QO8:45 08:30 09:00 Lab Number : Na+ 139 139 138 ( 135 - 145 } mmol /L K+ 4.2 4.1 4.5 ( 3.5 - 5.2 } mmol /L Chloride 101 104 105 ( 95 - 110 ) mmol /L', 'CO2', '27 25 24 ( BB - 323 } mmol /L', 'UREA', '6.0 5.8 4.2 ( 3.5 - 8.0 } mmol /L', 'CREAN', '54 52 45 ( 45 - 90 } umol /L', 'EGFR', '> 90 > 90 > 90 ( > 59 ) mL / min/1.73m2 T.Protein 65 67 68 ( 60 - 80 } g / L Albumin 38 35 37 ( 35 - 50 ) g / L Globulin 27 32 31 ( 23 - 39 ) g / L', 'ALP', 'a7 B7 68 ( 30 - 110 ) U / L Bilirubin 9 7 7 ( 3 - 30 ) umol /L', 'GGT', '16 12 14 ( 5 - 35 ) U / L', 'AST', '13 15 * 41 ( 5 - 30 ) U / L', 'ALT', 'zal 17 15 ( 5 - 35 ) U / L 86820229 Within reference intervals . Please note : from 09.11.23 new reference intervals apply for Liver Funetion Tests . These are sourced from the RCPA Harmonised Reference Intervals ( v2.0 ) document .', 'CRP', '- R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12', '- R ,', 'ESR', '- R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 2 of 7 REMOVED Peghy « Ao G4 AG +49 : 6 — > CLINICAL LABORATOURIE Page HHS lj *', 'I2', 'mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BIOCHEMISTRY C REACTIVE FPROTEIN (', 'CRP', ') SPECIMEN : SHRUM REMOVED In the setting of infection ,', 'CRP', 'levels +100 mg / L are supportive of bacterial rather than viral aetiology . Note resulta from this', 'CRP', 'aasay should not be used for cardiac risk agssedament . Please request the high sensitivity assay ( hsCRP ) inatead . BIOCHEMISTRY GLUCOSE Date Time Lab # Collection Type Specimen Glucose ( mmol / L ) 95/02/24 08:45 618202xxx29 Fasting serum * # 1.7 12351282555529 Elevated fasting', 'GLUC', 'and HbAlc are consistent with diabetes . Suggest annual monitoring with urine', 'ALB', 'to detect diabetic nephropathy . Glucose Reference Ranges Random 3.0 - 6.9 mmol / L Fasting 3.0 - 5.4 mmol / L 1 Hour post prandial 3.0 - 11.0 mmol / L 2 Hour post prandial 3.0 - 7.7 mmol / L Specimen Legend : Fl - ox = Fluoride oxalate , serum = Serum , np = Non - Preserved', 'CRP', '- R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12', '- R ,', 'ESR', '- R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 3 of 7 REMOVED Feghy « Ao G4 yAG +4921 — > CLINICAL LABORATURIE Page HH4 li *', 'I2', 'Anica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BLOCHEMISTRY HAEMOGLOBIN Alc SPECIMEN : WHOLE BLOOD ITFCC DCCT Date Coll Time Req . No . HbAle ( mmol / mol ) HbAlca ( % } 05/03/24 08:45 86820229 BR ?', 'KK', '7.4 07/12/22 08:30 72256123 BS', 'KK', \"7.5 BE6820229 RECOMMENDATIONS Consider review of diabetes management , if appropriate . Suggest repeat HbAle in 3 months . Note that urine microalbumin is now due . INTERPRETATION CRITERIA DIAGNOSIS . A HbAle greater than or equal to 48 mmol / mol ( 6.5 ¥ % ) 18 conalatent With diabetes . Consider OGTT or repeat HbAlec for confirmation . HbAlec 6.0 - 6.4 % 18 consistent with prediabetes . Repeat testing annuall 18 recommended . ( ADS position atatement 2020 ) MONITORING . The Australian Diabetes Society ( ADS ) recommenda individualised HbAlc targeta depending on the patient 's age , comorbidities and any Hypoglycaemia ( ADS position statement 2009 ) . A general target of less than or equal to 53 mmol / mol ( 7.0 % ) is often used . Please note that\", 'HGB', 'Alec resulta may be influenced by conditiong affecting red cells or their survival times such as haemoglobinopathies anaemias , recent transfusion or blood loss . HbAle tested on Roche ¢513 using Gen. 3 assay .', 'CRP', '- R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12', '- R ,', 'ESR', '- R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 4 of 7 REMOVED Peghy « Ao G4 AG +49 « 38 — > CLINICAL LABORATORIE Page HHS lj *', 'I2', 'mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BIOCHEMISTRY LIPID STUDIES SPECIMEN : SERUM Date : 05/02/24 07/12/22 10/06/21 Coll . Time : 08:45 08:30 09:00 Desirable Range Lab Number : Faating Status Fasting Faating Fasting Total Chol . * 6.0 * 6.23 * 6.2 ( « 5.6 ) mmol / HDL Chel . * 1.1 1.1 * 1.0 ( > 1.1 ) mmol / LDL Chel . * 3.7 * 3.9 * 4,3 ( x 3.1 ) mmol / Non - HDL Chel . * 4.9 * 5.1 * 5.2 ( x 4.1 ) mmol / Triglyceride * 2.6 * 2.7 = * 2.0 ( < 2.1 ) mmol / LDL / HDL Ratio 3.4 3.6 4.3 Chol / HDL Ratio 5.4 5.6 6.2 86820229 History of Diabetes . Interpret in conjunction with other cardiovascular risk factors or treatment targeta . Recommended targeta for high riak patients are Total cholesterol < « 4.0 mmol / L HDL Cholesterol > 1.0 mmol / L LDL Cholesterol = < 2.5 mmol / L ( < 1.8 mmol / L for very high risk ) Non - HDL Cholesterol “ = 3.3 mmol / L ( < « 2.5 mmol / L for very high risk ) Fasting triglycerides < 2.0 mmol / L Lipid ranges and targets are from the AACB Guideline for Harmonised Lipi Reporting ( 2018 ) Target values need to be individualised based on clinical assesament of overall risk . See the AusCVD Risk calculator at www.cvdcheck.org.au', 'CRP', '- R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12', '- R ,', 'ESR', '- R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 5 of 7 REMOVED Peghy « Ao G4 AG +49 554 — > CLINICAL LABORATORIE Page HHo lj *', 'I2', 'mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BIOCHEMISTRY LRON STUDIES SPECIMEN : SHRUM Date : 05/02/24 10/06/21 Coll . Time : O8:45 09:00 Lab Number : Tron 14.6 * 8.7 ( 10.0 - 30.0 ) umol/', 'TFER', '2.64 2.56 ( 2.10 - 3.80 ) g / L Saturation 22 * 14 ( 15 - 45 } %', 'FERR', '* 26 * 28 ( 30 - 300 ) ug /L 86820229 Fe3+ studies are consistent with iron deficiency . BIOCHEMISTRY VITAMIN Bl2 AND FOLATE SPECIMEN : SERUM / BLOOD Date : 05/02/24 10/06/21 Time : 08:45 09:00 Lab Number : Vitamin', 'vitB12', '412 526 pmol / L', 'vitB9', '> 54.5 nmol / L 86820229 Normal Bl2 result . RANGES Biz Serum', 'vitB9', 'Red Cell', 'vitB9', 'Normal > 180 > 10.90 > 450 Equivocal 150 - 180 8.0 - 10.0 350 - 450 Deficient « 150 - « 5.0 « 350 Vitamin Bl2 and', 'vitB9', 'analyses are performed on the Siemena Centaur/ Atellica .', 'CRP', '- R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12', '- R ,', 'ESR', '- R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 6 of 7 REMOVED Peabo 64 AG : 58 + BB — > CLINICAL LABORATURIE Page HH ? lj *', 'I2', 'mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria ENDOCRINOLOGY THYROID FUNCTION TEST SPECIMEN : SERUM Date : 05/02/24 07/12/22 10/06/21 Coll . Time : 08:45 08:30 09:00 Lab Number :', 'TSH', '2.37 2.31 2.30 ( 0.40 - 4,.00)mIU / L 868202295 Normal', 'TSH', 'level . BLOCHEMISTRY VITAMIN D SPECIMEN : SEHEREUM 25 - hydroxy REMOVED 86820229 Within normal limita . Interpretation : Vitamin D deficiency < 50 nmol / L Severe deficiency < 20 nmol / L COMMENT : Vitamin D sufficiency is defined as greater than or equal to 50 nmol / L at the end of winter ( level may need to be 10 - 20 nmol / L highe at the end of gummer ) . Reference : Position Statement . Vitamin D and Health in Adults in Australia and New Zealand . MJA,196(11 ): 686 - 687 , 2012 .', 'CRP', '- R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12', '- R ,', 'ESR', '- R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 7 of 7 REMOVED']\n",
      "Combined tokens: ['Peghy « Ao ¢4 AG +48 | 38 — > CLINICAL LABORATORIE Page HH1 lj *', 'I2 mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria HAEMATOLOGY SPECIMEN : WHOLE BLOOD Date : 05/02/24 07/12/22 10/06/21 ( # Refers to current Coll . Time : 08:45 08:30 09:00 result only ) Lab Number : HAEMOGLOEIN 138 133 126 ( 115 - 165 ) g / L', 'RBC 5.02 4.77 4.48 ( 3.80 - 5.50)x10l4 / L', 'HCT QO.45 0.43 O.41 ( 0.35 - 0.47 )', 'MCV 90 91 91 ( 80 - 99 ) CL', 'MCHC 27.5 27.9 28.1 ( 27.0 - 34.0)pgq', 'MCHC * 305 * 306 * 309 ( 310 - 360 ) g / L', 'RDW 14.1 12.8 12.9 ( 11.0 - 15.0)% wee 6.8 7.4 6.5 ( 4.0 - 11.0 } x107 / L', 'NEUT 2.4 3.8 2.7 ( 2.0 - 8.0 ) x“107 / L Lymphocytea 3.6 3.0 3.0 ( 1.0 - 4.0 ) x107 / L Monocytea 0.5 0.4 0.4 ( < 1.1 ) x107 / L', 'EOS 0.3 O.1 0.3 ( « 0.7 ) x107 / L', 'BASO < 0.1 0.0 < 0.1 ( fe 0.3 ) * x107 / L PLATELETS 308 336 200 ( 150 - 450 ) x107 / L', 'ESR 5 13 ( < 21 ) mm /h # 86820229 : Persistent red cell hypochromia . Serum ferritin is pending .', 'I2 1ron atores are normal consider thalasdaemia screen .', 'ESR is normal .', 'CRP - R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12 - R ,', 'ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 1 of 7 REMOVED Peghy « Ao ¢4 AG +48 52 — > CLINICAL LABORATORIE Page HHZ lj *', 'I2 mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria GENERAL CHEMISTEY SPECIMEN : SERUM Date : 05/02/24 07/12/22 10/06/21 Coll . Time : QO8:45 08:30 09:00 Lab Number : Na+ 139 139 138 ( 135 - 145 } mmol /L K+ 4.2 4.1 4.5 ( 3.5 - 5.2 } mmol /L Chloride 101 104 105 ( 95 - 110 ) mmol /L', 'CO2 27 25 24 ( BB - 323 } mmol /L', 'UREA 6.0 5.8 4.2 ( 3.5 - 8.0 } mmol /L', 'CREAN 54 52 45 ( 45 - 90 } umol /L', 'EGFR > 90 > 90 > 90 ( > 59 ) mL / min/1.73m2 T.Protein 65 67 68 ( 60 - 80 } g / L Albumin 38 35 37 ( 35 - 50 ) g / L Globulin 27 32 31 ( 23 - 39 ) g / L', 'ALP a7 B7 68 ( 30 - 110 ) U / L Bilirubin 9 7 7 ( 3 - 30 ) umol /L', 'GGT 16 12 14 ( 5 - 35 ) U / L', 'AST 13 15 * 41 ( 5 - 30 ) U / L', 'ALT zal 17 15 ( 5 - 35 ) U / L 86820229 Within reference intervals . Please note : from 09.11.23 new reference intervals apply for Liver Funetion Tests . These are sourced from the RCPA Harmonised Reference Intervals ( v2.0 ) document .', 'CRP - R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12 - R ,', 'ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 2 of 7 REMOVED Peghy « Ao G4 AG +49 : 6 — > CLINICAL LABORATOURIE Page HHS lj *', 'I2 mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BIOCHEMISTRY C REACTIVE FPROTEIN (', 'CRP ) SPECIMEN : SHRUM REMOVED In the setting of infection ,', 'CRP levels +100 mg / L are supportive of bacterial rather than viral aetiology . Note resulta from this', 'CRP aasay should not be used for cardiac risk agssedament . Please request the high sensitivity assay ( hsCRP ) inatead . BIOCHEMISTRY GLUCOSE Date Time Lab # Collection Type Specimen Glucose ( mmol / L ) 95/02/24 08:45 618202xxx29 Fasting serum * # 1.7 12351282555529 Elevated fasting', 'GLUC and HbAlc are consistent with diabetes . Suggest annual monitoring with urine', 'ALB to detect diabetic nephropathy . Glucose Reference Ranges Random 3.0 - 6.9 mmol / L Fasting 3.0 - 5.4 mmol / L 1 Hour post prandial 3.0 - 11.0 mmol / L 2 Hour post prandial 3.0 - 7.7 mmol / L Specimen Legend : Fl - ox = Fluoride oxalate , serum = Serum , np = Non - Preserved', 'CRP - R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12 - R ,', 'ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 3 of 7 REMOVED Feghy « Ao G4 yAG +4921 — > CLINICAL LABORATURIE Page HH4 li *', \"I2 Anica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BLOCHEMISTRY HAEMOGLOBIN Alc SPECIMEN : WHOLE BLOOD ITFCC DCCT Date Coll Time Req . No . HbAle ( mmol / mol ) HbAlca ( % } 05/03/24 08:45 86820229 BR ? KK 7.4 07/12/22 08:30 72256123 BS KK 7.5 BE6820229 RECOMMENDATIONS Consider review of diabetes management , if appropriate . Suggest repeat HbAle in 3 months . Note that urine microalbumin is now due . INTERPRETATION CRITERIA DIAGNOSIS . A HbAle greater than or equal to 48 mmol / mol ( 6.5 ¥ % ) 18 conalatent With diabetes . Consider OGTT or repeat HbAlec for confirmation . HbAlec 6.0 - 6.4 % 18 consistent with prediabetes . Repeat testing annuall 18 recommended . ( ADS position atatement 2020 ) MONITORING . The Australian Diabetes Society ( ADS ) recommenda individualised HbAlc targeta depending on the patient 's age , comorbidities and any Hypoglycaemia ( ADS position statement 2009 ) . A general target of less than or equal to 53 mmol / mol ( 7.0 % ) is often used . Please note that\", 'HGB Alec resulta may be influenced by conditiong affecting red cells or their survival times such as haemoglobinopathies anaemias , recent transfusion or blood loss . HbAle tested on Roche ¢513 using Gen. 3 assay .', 'CRP - R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12 - R ,', 'ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 4 of 7 REMOVED Peghy « Ao G4 AG +49 « 38 — > CLINICAL LABORATORIE Page HHS lj *', 'I2 mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BIOCHEMISTRY LIPID STUDIES SPECIMEN : SERUM Date : 05/02/24 07/12/22 10/06/21 Coll . Time : 08:45 08:30 09:00 Desirable Range Lab Number : Faating Status Fasting Faating Fasting Total Chol . * 6.0 * 6.23 * 6.2 ( « 5.6 ) mmol / HDL Chel . * 1.1 1.1 * 1.0 ( > 1.1 ) mmol / LDL Chel . * 3.7 * 3.9 * 4,3 ( x 3.1 ) mmol / Non - HDL Chel . * 4.9 * 5.1 * 5.2 ( x 4.1 ) mmol / Triglyceride * 2.6 * 2.7 = * 2.0 ( < 2.1 ) mmol / LDL / HDL Ratio 3.4 3.6 4.3 Chol / HDL Ratio 5.4 5.6 6.2 86820229 History of Diabetes . Interpret in conjunction with other cardiovascular risk factors or treatment targeta . Recommended targeta for high riak patients are Total cholesterol < « 4.0 mmol / L HDL Cholesterol > 1.0 mmol / L LDL Cholesterol = < 2.5 mmol / L ( < 1.8 mmol / L for very high risk ) Non - HDL Cholesterol “ = 3.3 mmol / L ( < « 2.5 mmol / L for very high risk ) Fasting triglycerides < 2.0 mmol / L Lipid ranges and targets are from the AACB Guideline for Harmonised Lipi Reporting ( 2018 ) Target values need to be individualised based on clinical assesament of overall risk . See the AusCVD Risk calculator at www.cvdcheck.org.au', 'CRP - R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12 - R ,', 'ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 5 of 7 REMOVED Peghy « Ao G4 AG +49 554 — > CLINICAL LABORATORIE Page HHo lj *', 'I2 mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria BIOCHEMISTRY LRON STUDIES SPECIMEN : SHRUM Date : 05/02/24 10/06/21 Coll . Time : O8:45 09:00 Lab Number : Tron 14.6 * 8.7 ( 10.0 - 30.0 ) umol/', 'TFER 2.64 2.56 ( 2.10 - 3.80 ) g / L Saturation 22 * 14 ( 15 - 45 } %', 'FERR * 26 * 28 ( 30 - 300 ) ug /L 86820229 Fe3+ studies are consistent with iron deficiency . BIOCHEMISTRY VITAMIN Bl2 AND FOLATE SPECIMEN : SERUM / BLOOD Date : 05/02/24 10/06/21 Time : 08:45 09:00 Lab Number : Vitamin', 'vitB12 412 526 pmol / L', 'vitB9 > 54.5 nmol / L 86820229 Normal Bl2 result . RANGES Biz Serum', 'vitB9 Red Cell', 'vitB9 Normal > 180 > 10.90 > 450 Equivocal 150 - 180 8.0 - 10.0 350 - 450 Deficient « 150 - « 5.0 « 350 Vitamin Bl2 and', 'vitB9 analyses are performed on the Siemena Centaur/ Atellica .', 'CRP - R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12 - R ,', 'ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 6 of 7 REMOVED Peabo 64 AG : 58 + BB — > CLINICAL LABORATURIE Page HH ? lj *', 'I2 mMnica LABORATORY 3427 - 3420 Referred : 02/02/24 Clinical Notes : diabtetic urticaria ENDOCRINOLOGY THYROID FUNCTION TEST SPECIMEN : SERUM Date : 05/02/24 07/12/22 10/06/21 Coll . Time : 08:45 08:30 09:00 Lab Number :', 'TSH 2.37 2.31 2.30 ( 0.40 - 4,.00)mIU / L 868202295 Normal', 'TSH level . BLOCHEMISTRY VITAMIN D SPECIMEN : SEHEREUM 25 - hydroxy REMOVED 86820229 Within normal limita . Interpretation : Vitamin D deficiency < 50 nmol / L Severe deficiency < 20 nmol / L COMMENT : Vitamin D sufficiency is defined as greater than or equal to 50 nmol / L at the end of winter ( level may need to be 10 - 20 nmol / L highe at the end of gummer ) . Reference : Position Statement . Vitamin D and Health in Adults in Australia and New Zealand . MJA,196(11 ): 686 - 687 , 2012 .', 'CRP - R , GLS - R , GHB - R , OHD - R , RAS - W ,', 'vitB12 - R ,', 'ESR - R , FBE - R,1I5 - R , LIP - R , ECU - R , LET-+4++4 + Page : 7 of 7 REMOVED']\n",
      "Extracted results: []\n",
      "Processing file: ./files/data_0b8706dc-c9af-4c6b-887d-2f85b5a511e7.csv\n",
      "Concatenated strings: 13/02/2024 17:17 Clinical notes : ? HYPERTENSION ? ANXIETY RELATED / WHITE COAT HYPERTENSION ( NEEDS EXCLUDING ) removed Clinical Notes : ? HYPERTENSION ? ANXIETY RELATED / WHITE COAT HYPERTENSION ( NEEDS EXCLUDING ) Ambulatory Blood Pressure Monitoring Start date and time\n",
      "Regex pattern: (\\b(?:11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|Al|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|As|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|Br-|CRP|Cd2+|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|Cl-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|Cu2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|hs-cTnI|HIST|HCYS|IGC|IGC%|IPF|IRF|igA|igD|igE|igG|igM|BILIIN|IGF1|I2|Fe3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|Pb2+|LEP|LAP|LPSE|LPPA|Li+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|Mg2+|Mn2+|MCH|MCHC|MCV|MPV|MELAT|Hg2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCs|OXYT|PCPP|PTH|pCO2|pO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-He|RETI|RR%|SRNE|Na+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|vitA|vitB1|vitB12|vitB2|vitB3|vitB5|vitB6|vitB9|vitC|vitD|vitE|vitK1|WBC|Zn2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAb|TgAb|11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|AL|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|AS|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|BR-|CRP|CD2+|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CL-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|CU2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|HS-CTNI|HIST|HCYS|IGC|IGC%|IPF|IRF|IGA|IGD|IGE|IGG|IGM|BILIIN|IGF1|I2|FE3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|PB2+|LEP|LAP|LPSE|LPPA|LI+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|MG2+|MN2+|MCH|MCHC|MCV|MPV|MELAT|HG2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCS|OXYT|PCPP|PTH|PCO2|PO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-HE|RETI|RR%|SRNE|NA+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|VITA|VITB1|VITB12|VITB2|VITB3|VITB5|VITB6|VITB9|VITC|VITD|VITE|VITK1|WBC|ZN2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAB|TGAB)\\b)[\\s,:.]+\n",
      "Tokens: ['13/02/2024 17:17 Clinical notes : ? HYPERTENSION ? ANXIETY RELATED / WHITE COAT HYPERTENSION ( NEEDS EXCLUDING ) removed Clinical Notes : ? HYPERTENSION ? ANXIETY RELATED / WHITE COAT HYPERTENSION ( NEEDS EXCLUDING ) Ambulatory Blood Pressure Monitoring Start date and time']\n",
      "Combined tokens: ['13/02/2024 17:17 Clinical notes : ? HYPERTENSION ? ANXIETY RELATED / WHITE COAT HYPERTENSION ( NEEDS EXCLUDING ) removed Clinical Notes : ? HYPERTENSION ? ANXIETY RELATED / WHITE COAT HYPERTENSION ( NEEDS EXCLUDING ) Ambulatory Blood Pressure Monitoring Start date and time']\n",
      "Extracted results: []\n",
      "Processing file: ./files/data_0ea75106-2a9d-4adc-9dad-33256e7d9aad.csv\n",
      "Concatenated strings: 29 APR MRN : Name : Ph : Age : 64 + Yrs DOB :   Sex : Male Notes : ? ANAEMIC ( CHEMISTRY ~ Result PLEVicus resuits Fox , comparison omy Date : 26/94/19 noe ference Time : 15:40 V£or this Request No . :   Units collecrion ) Electrolytes ( serum / plasma ) Na+ 142 mmol / L [ 185 - 145 ] K+ 4.0 mmol / L ( 2.5 - 5.2 ] Chloride 106 mmol / L [ 95 - 110 ] CO2 28 mmol / L [ 22 - 32 ] UREA 4.1 mmol / L [ 4.0 - 9.0 ] CREAN 89 umol / L [ 60 - 110 ] EGFR 79 mL / mn/1.73m2[>60 ] Uric acid 0.44 mmol / L [ 0.25 - 0.50 ] Calcium 2.40 mmol / L [ 2.10 - 2.60 ] Calcium ( corr . Alb ) 2.40 mmol / L [ 2.10 - 2.60 ] Magnesium 0.81 mmol / L [ 0.70 - 1.10 ] Inorganic P5+ 1.12 mmol / L [ 0.70 - 1.50 ] EGFR comment gfrmild Range Comment COM1 Comments : (\n",
      "Regex pattern: (\\b(?:11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|Al|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|As|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|Br-|CRP|Cd2+|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|Cl-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|Cu2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|hs-cTnI|HIST|HCYS|IGC|IGC%|IPF|IRF|igA|igD|igE|igG|igM|BILIIN|IGF1|I2|Fe3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|Pb2+|LEP|LAP|LPSE|LPPA|Li+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|Mg2+|Mn2+|MCH|MCHC|MCV|MPV|MELAT|Hg2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCs|OXYT|PCPP|PTH|pCO2|pO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-He|RETI|RR%|SRNE|Na+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|vitA|vitB1|vitB12|vitB2|vitB3|vitB5|vitB6|vitB9|vitC|vitD|vitE|vitK1|WBC|Zn2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAb|TgAb|11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|AL|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|AS|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|BR-|CRP|CD2+|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CL-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|CU2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|HS-CTNI|HIST|HCYS|IGC|IGC%|IPF|IRF|IGA|IGD|IGE|IGG|IGM|BILIIN|IGF1|I2|FE3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|PB2+|LEP|LAP|LPSE|LPPA|LI+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|MG2+|MN2+|MCH|MCHC|MCV|MPV|MELAT|HG2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCS|OXYT|PCPP|PTH|PCO2|PO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-HE|RETI|RR%|SRNE|NA+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|VITA|VITB1|VITB12|VITB2|VITB3|VITB5|VITB6|VITB9|VITC|VITD|VITE|VITK1|WBC|ZN2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAB|TGAB)\\b)[\\s,:.]+\n",
      "Tokens: ['29 APR MRN : Name : Ph : Age : 64 + Yrs DOB :   Sex : Male Notes : ? ANAEMIC ( CHEMISTRY ~ Result PLEVicus resuits Fox , comparison omy Date : 26/94/19 noe ference Time : 15:40 V£or this Request No . :   Units collecrion ) Electrolytes ( serum / plasma ) Na+ 142 mmol / L [ 185 - 145 ] K+ 4.0 mmol / L ( 2.5 - 5.2 ] Chloride 106 mmol / L [ 95 - 110 ]', 'CO2', '28 mmol / L [ 22 - 32 ]', 'UREA', '4.1 mmol / L [ 4.0 - 9.0 ]', 'CREAN', '89 umol / L [ 60 - 110 ]', 'EGFR', '79 mL / mn/1.73m2[>60 ] Uric acid 0.44 mmol / L [ 0.25 - 0.50 ] Calcium 2.40 mmol / L [ 2.10 - 2.60 ] Calcium ( corr . Alb ) 2.40 mmol / L [ 2.10 - 2.60 ] Magnesium 0.81 mmol / L [ 0.70 - 1.10 ] Inorganic P5+ 1.12 mmol / L [ 0.70 - 1.50 ]', 'EGFR', 'comment gfrmild Range Comment COM1 Comments : (']\n",
      "Combined tokens: ['29 APR MRN : Name : Ph : Age : 64 + Yrs DOB :   Sex : Male Notes : ? ANAEMIC ( CHEMISTRY ~ Result PLEVicus resuits Fox , comparison omy Date : 26/94/19 noe ference Time : 15:40 V£or this Request No . :   Units collecrion ) Electrolytes ( serum / plasma ) Na+ 142 mmol / L [ 185 - 145 ] K+ 4.0 mmol / L ( 2.5 - 5.2 ] Chloride 106 mmol / L [ 95 - 110 ]', 'CO2 28 mmol / L [ 22 - 32 ]', 'UREA 4.1 mmol / L [ 4.0 - 9.0 ]', 'CREAN 89 umol / L [ 60 - 110 ]', 'EGFR 79 mL / mn/1.73m2[>60 ] Uric acid 0.44 mmol / L [ 0.25 - 0.50 ] Calcium 2.40 mmol / L [ 2.10 - 2.60 ] Calcium ( corr . Alb ) 2.40 mmol / L [ 2.10 - 2.60 ] Magnesium 0.81 mmol / L [ 0.70 - 1.10 ] Inorganic P5+ 1.12 mmol / L [ 0.70 - 1.50 ]', 'EGFR comment gfrmild Range Comment COM1 Comments : (']\n",
      "Extracted results: [{'parameter': 'EGFR', 'value': '79', 'unit': 'ml'}]\n",
      "Processing file: ./files/data_0c848136-de54-49eb-a3c4-b04dda11ef42.csv\n",
      "Concatenated strings: HAEMATOLOGY 15 BLOOD - EDTA Result Range Units ESR 2 0 - 20 mm / h @ FULL BLOOD EXAMINATION HAEMOGLOBIN 122 110 - 150 g / L a @ a RBC ( RBC ) 46 42 - 56 i | e a Mean Cell Volume 102.0*H 78.0 - 98.0 — f a di Mean Cell HGB 27.0 26.0 - 34.0 pg a @ a MCHC 29.0*L 31.0 - 370 pol fe a Haematocrit 47.0 35.0 - 47.0 % a @ a PLATELETS 338 150 - 450 ‘ oro . i e a LEUCOCYTES ( WBCs ) 7.3 4.0- 11.0 1049 / L a @ a NEUT 4.8 2.0 - 7.5 1o.o / L @ a Lymphocytes 1.8 1.0 - 4.0 a | @ a MONO 0.5 0.0 - 1.0 1049 / L @ pe EOS 0.2 0.0 - 0.6 1049 / L e || BASO 0.1 0.0 - 0.2 1049 / L @ p RDW 15.6*H 11.0- 15.5 percent [ ij e Film Comment Test performed by accredited laboratory NATA : BLOOD - SERUM Result Range Units UEC ( Renal ) SODIUM 138 135 - 145 mmol / L e@ a POTASSIUM 4.5 3.5 - 5.2 mmol / L e a CHLORIDE 102 95 - 110 mmol / L e a BICARBONATE 24 20 - 32 mmol / L e a Anion Gap 16 8 - 16 mmol / L e a UREA 3.7 2.5 - 7.0 mmol / L e@ a CREATININE ( mmol / L ) 0.06 0.05 - 0.10 mmol / L e@ a CREAN 62 45 - 90 umol / L e@ a Estimated EGFR > 90 > 90 ml / min/1 _ _ _ - e * ) Result outside normal reference range H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range UEC Comment ELEVATED ANION GAP : An elevated anion gap indicates metabolic acidosis . In uncontrolled diabetes , there is an increase in ketoacids due to metabolism of ketones . In these conditions , HCO3 concentrations decrease by acting as a buffer against the increased presence of acids ( as a result of the underlying condition ) . The HCO3 is consumed resulting in a high anion gap . ESTIMATED EGFR COMMENT : EGFR ( mL / min/1.73m2 ) is calculated by the laboratory using the CKD - EPI formula EGFR > 90 mL / min/1.73 sq.m — - Normal EGFR LIVER FUNCTION TESTS BILIRUBIN ( TOTAL ) 13 0 - 20 umol / L e | ALP 97 30 - 110 units / L @ a GGT 23 5 - 35 units / L @ a ALT 33 10 - 35 units / L a @ a AST 25 10 - 35 units / L a r a PROTEIN - TOTAL 69 60 - 80 g / L a @ a ALBUMIN 35 33 - 48 g / L a e a GLOBULIN 33 26 - 39 g / L a @ a Corrected Calcium Profile CALCIUM 2.36 215 - 260 mmol / L Jy e a Calcium Adjusted 2.46 210 - 260 mmol / L e a PHOSPHATE 1.1 06 - 14 mmol / L i e a MAGNESIUM 0.77 . 070 - 110 mm e a LDH 169 120 - 250 units / L @ a URATE 0.330 015 - 040 mmol e a IRON STUDIES IRON 7.8 5.0 - 30.0 umo / L e a TRANSFERRIN 28 18 - 35 g / L a e a TFER Saturation 77*L 15 - 45 % o a @ a FERRITIN 32 30 - 150 ug / L sos e a ( * ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range Fe3+ Studies Comment Certain medications may affect results . Please correlate clinically . For assistance , please refer to the Fe3+ Studies Interpretation Table below : | CONDITION / SYMPTOM | IRON | TRANSFERRIN SATURATION | FERRITIN | | Inon Deficiency | Decreased | Decreased — — ' ||-:‘Decreased =| | Fe3+ Deficiency and | | Normal or | . \" Normal \" =| | Acute Phase Response | Decreased | Decreased | < 100 ug / L | | Acute Phase Response | Decreased | Decreased -—«'||:“*Increased =| | ‘ Tron Overload — « ||.:«Increased | ~ — ‘ Increased = — S—=|sIncreased =| FERRITIN COMMENT : Serum ferritin levels > 30 pg / L demonstrates healthy iron stores as long as co - existing inflammatory disease or hepatocellular damage are not present . 25 OH VITAMIN D 77 . 50 - 200 nmol / L i e a Vitamins Comment VITAMIN D COMMENT : Levels above 75 nmol / L may be desirable in people with osteoporosis or falls . 25 - hydroxy Vitamin D represents the body 's stores / reserves level . Vitamin D Deficiency Interpretation : Mild : 30 - 49 nmol / l Moderate : 12.5 - 29 nmol/1 Severe : < 12.5 nmol / l ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range LIPIDS CHOLESTEROL 5.0 0.0 - 5.5 mmol / L @ TRIGLYCERIDES 2.8*H 0.0- 2.0 mmol / L LIPID STUDIES HDL(Protective ) 0.8*L 1.2 - 2.0 mmol / L He Non - HDL Cholesterol 4.23*H < 4.0 mmol / L ry LDL(Atherogenic ) 3.0 0.0 - 3.4 mmol / L e Cholesterol / HDL Ratio 6.6 LDL / HDL RATIO ( Risk Factor ) 3.9*H 0.0 - 3.2 Trig / HDL Ratio 3.7*H 0.5 - 1.7 RATIO a ( * ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range Lipid Profile Comment Target Levels for the general population and the National Vascular Disease Prevention Alliance ( NVDPA ) treatment target levels for high - risk people ( known coronary heart and other arterial diseases , diabetes , chronic renal failure , Aboriginal and Torres Strait Islander peoples and familial hyperlipidaemic conditions ) are : Tot . Cholesterol LDL - Cholesterol HDL - Cholesterol General population : < 5.5 mmol / L < 2.0 mmol / L M : > = 1.0 , F : > = 1.2 mmol / L At risk individuals : < 4.0 mmol / L < 1.8 mmol / L Fasting TRIGL : < 2.0 mmol / L Non - HDL Cholesterol : < 2.5 mmol / L National guidelines generally specify specific targets , refer to www.cvdcheck.org.au ELEVATED TRIGLYCERIDES : Increased levels are seen in primary hypertriglyceridaemic states , and secondary to Nephrotic syndrome , Hypothyroidism , Pancreatitis , Diabetes mellitus , Alcoholism , oral contraceptive use or corticosteroid medication . LOW HDL - CHOLESTEROL : Low levels of HDL cholesterol and high levels of LDL cholesterol are associated with an increased risk of atherosclerotic vascular disease . Further assessment through Liposcreen LDL ( Lipid ) Subfractions to determine any other lipid anomalies . ELEVATED NON - HDL CHOLESTEROL LEVEL : Non - HDL cholesterol surpasses LDL cholesterol as a risk factor for CVD . Increased non - HDL Cholesterol is a significant marker for subclinical atherosclerosis . Non - HDL Cholesterol > 7.5mmol / L indicates an Increased risk of Familial Hypercholesterolaemia . TRIG / HDL RATIO COMMENT : HDL is closely related to triglycerides . Commonly , patients with elevated triglycerides also have low HDL levels , along with elevated clotting factor levels . The triglyceride / HDL ratio is found to be one of the better predictors of heart disease . Research shows that people with an elevated triglyceride / HDL have 16 times the risk of heart attack as those with a low / normal ratio . Therefore , in adults , the triglyceride / HDL ratio should ideally be below 2.0 TRIG / HDL Reference Range : < 0.9 Considered ideal ( minimal risk ) > 1.7 High ( moderate risk ) > 2.6 Very High ( high risk ) GLUCOSE ( FASTING ) 6.6*H 3.0 - 5.4 mmol / L a He ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range Glucose Comment ELEVATED FASTING GLUCOSE : Certain medications may affect results . Please correlate clinically . In patients with fasting plasma GLUC levels between 5.6 - 6.9 mmol / L or random plasma GLUC levels between 7.8 - 11.0 mmol / L , an oral Glucose Tolerance Test ( GTT ) should be performed if the patient is at high risk for diabetes . Irrespective of any GTT results , a fasting plasma GLUC 6.1 - 6.9 mmol / L indicates Impaired Fasting Glucose . In a patient with symptoms suggestive of Diabetes mellitus , the finding of a fasting plasma GLUC of > 7.0 mmol / L at least two hours following a meal , is diagnostic of Diabetes mellitus . The finding of either of these levels on two occasions , even in the absence of symptoms , is also diagnostic of Diabetes mellitus . INSULIN ( FASTING ) 34.1*H 0.0- 17.0 mU / L ile HOMA Score 10.0*H 0.0 - 2.5 RATIO ile Insulin Tolerance Test Comment FASTING INSULIN Comment : This reference interval is for fasting , normoglycaemic and non - obese population . A fasting GLUC should be performed together with fasting insulin to ascertain the HOMA score . The HOMA score is a standard measure of insulin resistance , It is calculated as follows ; ( Blood Glucose X Fasting Insulin ) / 22.5 . HOMA Resistance Grade < = 2.0 Normal 2.1 - 2.2 Borderline 2.3 - 3.0 Moderate > = 3.1 Severe BLOOD - EDTA GLYCOSYLATED HB 5.9*H 4.4 - 5.6 % a ai Glycated HGB Comment GLYCOSYLATED HAEMOGLOBIN COMMENT : The goal of diabetes therapy should be a glycated haemoglobin ( HbA Ic ) level of < 7 % . The treatment level should be re - evaluated if the HbAIc level is > 8 % . ENDOCRINOLOGY BLOOD - SERUM Result Range Units THYROID FUNCTION ASSESSMENT TSH 2.36   0.50 - 5.00 mU / L e a FREE TT4 16.9 12.0 - 22.0 pmol / L a e@ a FREE TT3 6.3 3.1 - 6.8 pmolL e@ a Reverse TT3 545.0*H 230.0 - 540.0 pmol / L e FT3 : Reverse TT3 Ratio ( X 100 ) 1.161 * L 1.200 - 2.200 a e a ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range THYROID TEST COMMENTS TSH has been adopted as the initial test of a thyroid function . Certain medications and conditions may affect results . Please correlate clinically . Repeat testing in 6 - 8 weeks if clinically indicated . Reference ranges developed using populations without thyroid disease suggest that the optimal TSH range for thyroid function should be 0.5 - 2.0OmIU / L. FREE TT4 and FREE TT3 Free TT4 and TT3 represent bioactive portion of thyroid hormone . The test results can identify functional or subclinical hyper- and hypothyroidism and overt hypo- and hyperthyroidism . TT4 converts to active TT3 or inactive rT3 . The results should always be interpreted in association with TSH . REVERSE TT3 levels can increase when peripheral conversion of TT4 to active TT3 is impaired . Peripheral thyroid imbalances may arise from nutrient deficiencies , heavy metal exposure , adrenal stress , enzyme deficiencies , and chronic illnesses . ELEVATED REVERSE TT3 LEVEL : A high or high normal rT3 level may inhibit the action of TT3 . Elevated rT3 may therefore lead to symptoms of hypothyroidism even if levels of TSH , TT4 & TT3 are adequate . Treatment Considerations : Consider TT3 therapy Assess and treat iron , selenium , iodine and zinc THYROID AUTO - Abs THYROID PEROXIDASE Ab . 9.0 0.0 - 35.0 [ U / mL e pS ANTITHYROGLOBULIN Ab . 12.9 0.0 - 115 [ U / mL @ || TSH RECEPTOR AB 0.8 0.0 - 1.8 Tests ordered : TSHA , ESR , HBA1C , INSF , LDH , MG , PHOS , URAT , FBE , IS , FATS , LFT , FGLU , LIP , UEC , TFA , ITTCOM , Corca Pro , EGFR , UECom , GLUCom , IMPEI , GHBCOM , VITD , THAB , CFee , HOMA ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range\n",
      "Regex pattern: (\\b(?:11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|Al|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|As|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|Br-|CRP|Cd2+|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|Cl-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|Cu2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|hs-cTnI|HIST|HCYS|IGC|IGC%|IPF|IRF|igA|igD|igE|igG|igM|BILIIN|IGF1|I2|Fe3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|Pb2+|LEP|LAP|LPSE|LPPA|Li+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|Mg2+|Mn2+|MCH|MCHC|MCV|MPV|MELAT|Hg2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCs|OXYT|PCPP|PTH|pCO2|pO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-He|RETI|RR%|SRNE|Na+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|vitA|vitB1|vitB12|vitB2|vitB3|vitB5|vitB6|vitB9|vitC|vitD|vitE|vitK1|WBC|Zn2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAb|TgAb|11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|AL|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|AS|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|BR-|CRP|CD2+|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CL-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|CU2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|HS-CTNI|HIST|HCYS|IGC|IGC%|IPF|IRF|IGA|IGD|IGE|IGG|IGM|BILIIN|IGF1|I2|FE3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|PB2+|LEP|LAP|LPSE|LPPA|LI+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|MG2+|MN2+|MCH|MCHC|MCV|MPV|MELAT|HG2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCS|OXYT|PCPP|PTH|PCO2|PO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-HE|RETI|RR%|SRNE|NA+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|VITA|VITB1|VITB12|VITB2|VITB3|VITB5|VITB6|VITB9|VITC|VITD|VITE|VITK1|WBC|ZN2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAB|TGAB)\\b)[\\s,:.]+\n",
      "Tokens: ['HAEMATOLOGY 15 BLOOD - EDTA Result Range Units', 'ESR', '2 0 - 20 mm / h @ FULL BLOOD EXAMINATION HAEMOGLOBIN 122 110 - 150 g / L a @ a', 'RBC', '(', 'RBC', ') 46 42 - 56 i | e a Mean Cell Volume 102.0*H 78.0 - 98.0 — f a di Mean Cell', 'HGB', '27.0 26.0 - 34.0 pg a @ a', 'MCHC', '29.0*L 31.0 - 370 pol fe a Haematocrit 47.0 35.0 - 47.0 % a @ a PLATELETS 338 150 - 450 ‘ oro . i e a LEUCOCYTES ( WBCs ) 7.3 4.0- 11.0 1049 / L a @ a', 'NEUT', '4.8 2.0 - 7.5 1o.o / L @ a Lymphocytes 1.8 1.0 - 4.0 a | @ a', 'MONO', '0.5 0.0 - 1.0 1049 / L @ pe', 'EOS', '0.2 0.0 - 0.6 1049 / L e ||', 'BASO', '0.1 0.0 - 0.2 1049 / L @ p', 'RDW', '15.6*H 11.0- 15.5 percent [ ij e Film Comment Test performed by accredited laboratory NATA : BLOOD - SERUM Result Range Units UEC ( Renal ) SODIUM 138 135 - 145 mmol / L e@ a POTASSIUM 4.5 3.5 - 5.2 mmol / L e a CHLORIDE 102 95 - 110 mmol / L e a BICARBONATE 24 20 - 32 mmol / L e a Anion Gap 16 8 - 16 mmol / L e a', 'UREA', '3.7 2.5 - 7.0 mmol / L e@ a CREATININE ( mmol / L ) 0.06 0.05 - 0.10 mmol / L e@ a', 'CREAN', '62 45 - 90 umol / L e@ a Estimated', 'EGFR', '> 90 > 90 ml / min/1 _ _ _ - e * ) Result outside normal reference range H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range UEC Comment ELEVATED ANION GAP : An elevated anion gap indicates metabolic acidosis . In uncontrolled diabetes , there is an increase in ketoacids due to metabolism of ketones . In these conditions ,', 'HCO3', 'concentrations decrease by acting as a buffer against the increased presence of acids ( as a result of the underlying condition ) . The', 'HCO3', 'is consumed resulting in a high anion gap . ESTIMATED', 'EGFR', 'COMMENT :', 'EGFR', '( mL / min/1.73m2 ) is calculated by the laboratory using the CKD - EPI formula', 'EGFR', '> 90 mL / min/1.73 sq.m — - Normal', 'EGFR', 'LIVER FUNCTION TESTS BILIRUBIN ( TOTAL ) 13 0 - 20 umol / L e |', 'ALP', '97 30 - 110 units / L @ a', 'GGT', '23 5 - 35 units / L @ a', 'ALT', '33 10 - 35 units / L a @ a', 'AST', '25 10 - 35 units / L a r a PROTEIN - TOTAL 69 60 - 80 g / L a @ a ALBUMIN 35 33 - 48 g / L a e a GLOBULIN 33 26 - 39 g / L a @ a Corrected Calcium Profile CALCIUM 2.36 215 - 260 mmol / L Jy e a Calcium Adjusted 2.46 210 - 260 mmol / L e a PHOSPHATE 1.1 06 - 14 mmol / L i e a MAGNESIUM 0.77 . 070 - 110 mm e a', 'LDH', '169 120 - 250 units / L @ a URATE 0.330 015 - 040 mmol e a IRON STUDIES IRON 7.8 5.0 - 30.0 umo / L e a TRANSFERRIN 28 18 - 35 g / L a e a', 'TFER', 'Saturation 77*L 15 - 45 % o a @ a FERRITIN 32 30 - 150 ug / L sos e a ( * ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range Fe3+ Studies Comment Certain medications may affect results . Please correlate clinically . For assistance , please refer to the Fe3+ Studies Interpretation Table below : | CONDITION / SYMPTOM | IRON | TRANSFERRIN SATURATION | FERRITIN | | Inon Deficiency | Decreased | Decreased — — \\' ||-:‘Decreased =| | Fe3+ Deficiency and | | Normal or | . \" Normal \" =| | Acute Phase Response | Decreased | Decreased | < 100 ug / L | | Acute Phase Response | Decreased | Decreased -—«\\'||:“*Increased =| | ‘ Tron Overload — « ||.:«Increased | ~ — ‘ Increased = — S—=|sIncreased =| FERRITIN COMMENT : Serum ferritin levels > 30 pg / L demonstrates healthy iron stores as long as co - existing inflammatory disease or hepatocellular damage are not present . 25 OH VITAMIN D 77 . 50 - 200 nmol / L i e a Vitamins Comment VITAMIN D COMMENT : Levels above 75 nmol / L may be desirable in people with osteoporosis or falls . 25 - hydroxy Vitamin D represents the body \\'s stores / reserves level . Vitamin D Deficiency Interpretation : Mild : 30 - 49 nmol / l Moderate : 12.5 - 29 nmol/1 Severe : < 12.5 nmol / l ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range LIPIDS CHOLESTEROL 5.0 0.0 - 5.5 mmol / L @ TRIGLYCERIDES 2.8*H 0.0- 2.0 mmol / L LIPID STUDIES HDL(Protective ) 0.8*L 1.2 - 2.0 mmol / L He Non - HDL Cholesterol 4.23*H < 4.0 mmol / L ry LDL(Atherogenic ) 3.0 0.0 - 3.4 mmol / L e Cholesterol / HDL Ratio 6.6 LDL / HDL RATIO ( Risk Factor ) 3.9*H 0.0 - 3.2 Trig / HDL Ratio 3.7*H 0.5 - 1.7 RATIO a ( * ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range Lipid Profile Comment Target Levels for the general population and the National Vascular Disease Prevention Alliance ( NVDPA ) treatment target levels for high - risk people ( known coronary heart and other arterial diseases , diabetes , chronic renal failure , Aboriginal and Torres Strait Islander peoples and familial hyperlipidaemic conditions ) are : Tot . Cholesterol LDL - Cholesterol HDL - Cholesterol General population : < 5.5 mmol / L < 2.0 mmol / L M : > = 1.0 , F : > = 1.2 mmol / L At risk individuals : < 4.0 mmol / L < 1.8 mmol / L Fasting', 'TRIGL', '< 2.0 mmol / L Non - HDL Cholesterol : < 2.5 mmol / L National guidelines generally specify specific targets , refer to www.cvdcheck.org.au ELEVATED TRIGLYCERIDES : Increased levels are seen in primary hypertriglyceridaemic states , and secondary to Nephrotic syndrome , Hypothyroidism , Pancreatitis , Diabetes mellitus , Alcoholism , oral contraceptive use or corticosteroid medication . LOW HDL - CHOLESTEROL : Low levels of HDL cholesterol and high levels of LDL cholesterol are associated with an increased risk of atherosclerotic vascular disease . Further assessment through Liposcreen LDL ( Lipid ) Subfractions to determine any other lipid anomalies . ELEVATED NON - HDL CHOLESTEROL LEVEL : Non - HDL cholesterol surpasses LDL cholesterol as a risk factor for CVD . Increased non - HDL Cholesterol is a significant marker for subclinical atherosclerosis . Non - HDL Cholesterol > 7.5mmol / L indicates an Increased risk of Familial Hypercholesterolaemia . TRIG / HDL RATIO COMMENT : HDL is closely related to triglycerides . Commonly , patients with elevated triglycerides also have low HDL levels , along with elevated clotting factor levels . The triglyceride / HDL ratio is found to be one of the better predictors of heart disease . Research shows that people with an elevated triglyceride / HDL have 16 times the risk of heart attack as those with a low / normal ratio . Therefore , in adults , the triglyceride / HDL ratio should ideally be below 2.0 TRIG / HDL Reference Range : < 0.9 Considered ideal ( minimal risk ) > 1.7 High ( moderate risk ) > 2.6 Very High ( high risk ) GLUCOSE ( FASTING ) 6.6*H 3.0 - 5.4 mmol / L a He ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range Glucose Comment ELEVATED FASTING GLUCOSE : Certain medications may affect results . Please correlate clinically . In patients with fasting plasma', 'GLUC', 'levels between 5.6 - 6.9 mmol / L or random plasma', 'GLUC', 'levels between 7.8 - 11.0 mmol / L , an oral Glucose Tolerance Test ( GTT ) should be performed if the patient is at high risk for diabetes . Irrespective of any GTT results , a fasting plasma', 'GLUC', '6.1 - 6.9 mmol / L indicates Impaired Fasting Glucose . In a patient with symptoms suggestive of Diabetes mellitus , the finding of a fasting plasma', 'GLUC', 'of > 7.0 mmol / L at least two hours following a meal , is diagnostic of Diabetes mellitus . The finding of either of these levels on two occasions , even in the absence of symptoms , is also diagnostic of Diabetes mellitus . INSULIN ( FASTING ) 34.1*H 0.0- 17.0 mU / L ile HOMA Score 10.0*H 0.0 - 2.5 RATIO ile Insulin Tolerance Test Comment FASTING INSULIN Comment : This reference interval is for fasting , normoglycaemic and non - obese population . A fasting', 'GLUC', 'should be performed together with fasting insulin to ascertain the HOMA score . The HOMA score is a standard measure of insulin resistance , It is calculated as follows ; ( Blood Glucose X Fasting Insulin ) / 22.5 . HOMA Resistance Grade < = 2.0 Normal 2.1 - 2.2 Borderline 2.3 - 3.0 Moderate > = 3.1 Severe BLOOD - EDTA GLYCOSYLATED HB 5.9*H 4.4 - 5.6 % a ai Glycated', 'HGB', 'Comment GLYCOSYLATED HAEMOGLOBIN COMMENT : The goal of diabetes therapy should be a glycated haemoglobin ( HbA Ic ) level of < 7 % . The treatment level should be re - evaluated if the HbAIc level is > 8 % . ENDOCRINOLOGY BLOOD - SERUM Result Range Units THYROID FUNCTION ASSESSMENT', 'TSH', '2.36   0.50 - 5.00 mU / L e a FREE', 'TT4', '16.9 12.0 - 22.0 pmol / L a e@ a FREE', 'TT3', '6.3 3.1 - 6.8 pmolL e@ a Reverse', 'TT3', '545.0*H 230.0 - 540.0 pmol / L e', 'FT3', 'Reverse', 'TT3', 'Ratio ( X 100 ) 1.161 * L 1.200 - 2.200 a e a ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range THYROID TEST COMMENTS', 'TSH', 'has been adopted as the initial test of a thyroid function . Certain medications and conditions may affect results . Please correlate clinically . Repeat testing in 6 - 8 weeks if clinically indicated . Reference ranges developed using populations without thyroid disease suggest that the optimal', 'TSH', 'range for thyroid function should be 0.5 - 2.0OmIU / L. FREE', 'TT4', 'and FREE', 'TT3', 'Free', 'TT4', 'and', 'TT3', 'represent bioactive portion of thyroid hormone . The test results can identify functional or subclinical hyper- and hypothyroidism and overt hypo- and hyperthyroidism .', 'TT4', 'converts to active', 'TT3', 'or inactive rT3 . The results should always be interpreted in association with', 'TSH', 'REVERSE', 'TT3', 'levels can increase when peripheral conversion of', 'TT4', 'to active', 'TT3', 'is impaired . Peripheral thyroid imbalances may arise from nutrient deficiencies , heavy metal exposure , adrenal stress , enzyme deficiencies , and chronic illnesses . ELEVATED REVERSE', 'TT3', 'LEVEL : A high or high normal rT3 level may inhibit the action of', 'TT3', 'Elevated rT3 may therefore lead to symptoms of hypothyroidism even if levels of', 'TSH', 'TT4', '&', 'TT3', 'are adequate . Treatment Considerations : Consider', 'TT3', 'therapy Assess and treat iron , selenium , iodine and zinc THYROID AUTO - Abs THYROID PEROXIDASE Ab . 9.0 0.0 - 35.0 [ U / mL e pS ANTITHYROGLOBULIN Ab . 12.9 0.0 - 115 [ U / mL @ ||', 'TSH', 'RECEPTOR AB 0.8 0.0 - 1.8 Tests ordered : TSHA ,', 'ESR', 'HBA1C', 'INSF ,', 'LDH', 'MG , PHOS , URAT , FBE , IS , FATS , LFT , FGLU , LIP , UEC , TFA , ITTCOM , Corca Pro ,', 'EGFR', 'UECom , GLUCom , IMPEI , GHBCOM ,', 'VITD', 'THAB , CFee , HOMA ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range']\n",
      "Combined tokens: ['HAEMATOLOGY 15 BLOOD - EDTA Result Range Units', 'ESR 2 0 - 20 mm / h @ FULL BLOOD EXAMINATION HAEMOGLOBIN 122 110 - 150 g / L a @ a', 'RBC (', 'RBC ) 46 42 - 56 i | e a Mean Cell Volume 102.0*H 78.0 - 98.0 — f a di Mean Cell', 'HGB 27.0 26.0 - 34.0 pg a @ a', 'MCHC 29.0*L 31.0 - 370 pol fe a Haematocrit 47.0 35.0 - 47.0 % a @ a PLATELETS 338 150 - 450 ‘ oro . i e a LEUCOCYTES ( WBCs ) 7.3 4.0- 11.0 1049 / L a @ a', 'NEUT 4.8 2.0 - 7.5 1o.o / L @ a Lymphocytes 1.8 1.0 - 4.0 a | @ a', 'MONO 0.5 0.0 - 1.0 1049 / L @ pe', 'EOS 0.2 0.0 - 0.6 1049 / L e ||', 'BASO 0.1 0.0 - 0.2 1049 / L @ p', 'RDW 15.6*H 11.0- 15.5 percent [ ij e Film Comment Test performed by accredited laboratory NATA : BLOOD - SERUM Result Range Units UEC ( Renal ) SODIUM 138 135 - 145 mmol / L e@ a POTASSIUM 4.5 3.5 - 5.2 mmol / L e a CHLORIDE 102 95 - 110 mmol / L e a BICARBONATE 24 20 - 32 mmol / L e a Anion Gap 16 8 - 16 mmol / L e a', 'UREA 3.7 2.5 - 7.0 mmol / L e@ a CREATININE ( mmol / L ) 0.06 0.05 - 0.10 mmol / L e@ a', 'CREAN 62 45 - 90 umol / L e@ a Estimated', 'EGFR > 90 > 90 ml / min/1 _ _ _ - e * ) Result outside normal reference range H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range UEC Comment ELEVATED ANION GAP : An elevated anion gap indicates metabolic acidosis . In uncontrolled diabetes , there is an increase in ketoacids due to metabolism of ketones . In these conditions ,', 'HCO3 concentrations decrease by acting as a buffer against the increased presence of acids ( as a result of the underlying condition ) . The', 'HCO3 is consumed resulting in a high anion gap . ESTIMATED', 'EGFR COMMENT :', 'EGFR ( mL / min/1.73m2 ) is calculated by the laboratory using the CKD - EPI formula', 'EGFR > 90 mL / min/1.73 sq.m — - Normal', 'EGFR LIVER FUNCTION TESTS BILIRUBIN ( TOTAL ) 13 0 - 20 umol / L e |', 'ALP 97 30 - 110 units / L @ a', 'GGT 23 5 - 35 units / L @ a', 'ALT 33 10 - 35 units / L a @ a', 'AST 25 10 - 35 units / L a r a PROTEIN - TOTAL 69 60 - 80 g / L a @ a ALBUMIN 35 33 - 48 g / L a e a GLOBULIN 33 26 - 39 g / L a @ a Corrected Calcium Profile CALCIUM 2.36 215 - 260 mmol / L Jy e a Calcium Adjusted 2.46 210 - 260 mmol / L e a PHOSPHATE 1.1 06 - 14 mmol / L i e a MAGNESIUM 0.77 . 070 - 110 mm e a', 'LDH 169 120 - 250 units / L @ a URATE 0.330 015 - 040 mmol e a IRON STUDIES IRON 7.8 5.0 - 30.0 umo / L e a TRANSFERRIN 28 18 - 35 g / L a e a', 'TFER Saturation 77*L 15 - 45 % o a @ a FERRITIN 32 30 - 150 ug / L sos e a ( * ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range Fe3+ Studies Comment Certain medications may affect results . Please correlate clinically . For assistance , please refer to the Fe3+ Studies Interpretation Table below : | CONDITION / SYMPTOM | IRON | TRANSFERRIN SATURATION | FERRITIN | | Inon Deficiency | Decreased | Decreased — — \\' ||-:‘Decreased =| | Fe3+ Deficiency and | | Normal or | . \" Normal \" =| | Acute Phase Response | Decreased | Decreased | < 100 ug / L | | Acute Phase Response | Decreased | Decreased -—«\\'||:“*Increased =| | ‘ Tron Overload — « ||.:«Increased | ~ — ‘ Increased = — S—=|sIncreased =| FERRITIN COMMENT : Serum ferritin levels > 30 pg / L demonstrates healthy iron stores as long as co - existing inflammatory disease or hepatocellular damage are not present . 25 OH VITAMIN D 77 . 50 - 200 nmol / L i e a Vitamins Comment VITAMIN D COMMENT : Levels above 75 nmol / L may be desirable in people with osteoporosis or falls . 25 - hydroxy Vitamin D represents the body \\'s stores / reserves level . Vitamin D Deficiency Interpretation : Mild : 30 - 49 nmol / l Moderate : 12.5 - 29 nmol/1 Severe : < 12.5 nmol / l ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range LIPIDS CHOLESTEROL 5.0 0.0 - 5.5 mmol / L @ TRIGLYCERIDES 2.8*H 0.0- 2.0 mmol / L LIPID STUDIES HDL(Protective ) 0.8*L 1.2 - 2.0 mmol / L He Non - HDL Cholesterol 4.23*H < 4.0 mmol / L ry LDL(Atherogenic ) 3.0 0.0 - 3.4 mmol / L e Cholesterol / HDL Ratio 6.6 LDL / HDL RATIO ( Risk Factor ) 3.9*H 0.0 - 3.2 Trig / HDL Ratio 3.7*H 0.5 - 1.7 RATIO a ( * ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range Lipid Profile Comment Target Levels for the general population and the National Vascular Disease Prevention Alliance ( NVDPA ) treatment target levels for high - risk people ( known coronary heart and other arterial diseases , diabetes , chronic renal failure , Aboriginal and Torres Strait Islander peoples and familial hyperlipidaemic conditions ) are : Tot . Cholesterol LDL - Cholesterol HDL - Cholesterol General population : < 5.5 mmol / L < 2.0 mmol / L M : > = 1.0 , F : > = 1.2 mmol / L At risk individuals : < 4.0 mmol / L < 1.8 mmol / L Fasting', 'TRIGL < 2.0 mmol / L Non - HDL Cholesterol : < 2.5 mmol / L National guidelines generally specify specific targets , refer to www.cvdcheck.org.au ELEVATED TRIGLYCERIDES : Increased levels are seen in primary hypertriglyceridaemic states , and secondary to Nephrotic syndrome , Hypothyroidism , Pancreatitis , Diabetes mellitus , Alcoholism , oral contraceptive use or corticosteroid medication . LOW HDL - CHOLESTEROL : Low levels of HDL cholesterol and high levels of LDL cholesterol are associated with an increased risk of atherosclerotic vascular disease . Further assessment through Liposcreen LDL ( Lipid ) Subfractions to determine any other lipid anomalies . ELEVATED NON - HDL CHOLESTEROL LEVEL : Non - HDL cholesterol surpasses LDL cholesterol as a risk factor for CVD . Increased non - HDL Cholesterol is a significant marker for subclinical atherosclerosis . Non - HDL Cholesterol > 7.5mmol / L indicates an Increased risk of Familial Hypercholesterolaemia . TRIG / HDL RATIO COMMENT : HDL is closely related to triglycerides . Commonly , patients with elevated triglycerides also have low HDL levels , along with elevated clotting factor levels . The triglyceride / HDL ratio is found to be one of the better predictors of heart disease . Research shows that people with an elevated triglyceride / HDL have 16 times the risk of heart attack as those with a low / normal ratio . Therefore , in adults , the triglyceride / HDL ratio should ideally be below 2.0 TRIG / HDL Reference Range : < 0.9 Considered ideal ( minimal risk ) > 1.7 High ( moderate risk ) > 2.6 Very High ( high risk ) GLUCOSE ( FASTING ) 6.6*H 3.0 - 5.4 mmol / L a He ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range Glucose Comment ELEVATED FASTING GLUCOSE : Certain medications may affect results . Please correlate clinically . In patients with fasting plasma', 'GLUC levels between 5.6 - 6.9 mmol / L or random plasma', 'GLUC levels between 7.8 - 11.0 mmol / L , an oral Glucose Tolerance Test ( GTT ) should be performed if the patient is at high risk for diabetes . Irrespective of any GTT results , a fasting plasma', 'GLUC 6.1 - 6.9 mmol / L indicates Impaired Fasting Glucose . In a patient with symptoms suggestive of Diabetes mellitus , the finding of a fasting plasma', 'GLUC of > 7.0 mmol / L at least two hours following a meal , is diagnostic of Diabetes mellitus . The finding of either of these levels on two occasions , even in the absence of symptoms , is also diagnostic of Diabetes mellitus . INSULIN ( FASTING ) 34.1*H 0.0- 17.0 mU / L ile HOMA Score 10.0*H 0.0 - 2.5 RATIO ile Insulin Tolerance Test Comment FASTING INSULIN Comment : This reference interval is for fasting , normoglycaemic and non - obese population . A fasting', 'GLUC should be performed together with fasting insulin to ascertain the HOMA score . The HOMA score is a standard measure of insulin resistance , It is calculated as follows ; ( Blood Glucose X Fasting Insulin ) / 22.5 . HOMA Resistance Grade < = 2.0 Normal 2.1 - 2.2 Borderline 2.3 - 3.0 Moderate > = 3.1 Severe BLOOD - EDTA GLYCOSYLATED HB 5.9*H 4.4 - 5.6 % a ai Glycated', 'HGB Comment GLYCOSYLATED HAEMOGLOBIN COMMENT : The goal of diabetes therapy should be a glycated haemoglobin ( HbA Ic ) level of < 7 % . The treatment level should be re - evaluated if the HbAIc level is > 8 % . ENDOCRINOLOGY BLOOD - SERUM Result Range Units THYROID FUNCTION ASSESSMENT', 'TSH 2.36   0.50 - 5.00 mU / L e a FREE', 'TT4 16.9 12.0 - 22.0 pmol / L a e@ a FREE', 'TT3 6.3 3.1 - 6.8 pmolL e@ a Reverse', 'TT3 545.0*H 230.0 - 540.0 pmol / L e', 'FT3 Reverse', 'TT3 Ratio ( X 100 ) 1.161 * L 1.200 - 2.200 a e a ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range THYROID TEST COMMENTS', 'TSH has been adopted as the initial test of a thyroid function . Certain medications and conditions may affect results . Please correlate clinically . Repeat testing in 6 - 8 weeks if clinically indicated . Reference ranges developed using populations without thyroid disease suggest that the optimal', 'TSH range for thyroid function should be 0.5 - 2.0OmIU / L. FREE', 'TT4 and FREE', 'TT3 Free', 'TT4 and', 'TT3 represent bioactive portion of thyroid hormone . The test results can identify functional or subclinical hyper- and hypothyroidism and overt hypo- and hyperthyroidism .', 'TT4 converts to active', 'TT3 or inactive rT3 . The results should always be interpreted in association with', 'TSH REVERSE', 'TT3 levels can increase when peripheral conversion of', 'TT4 to active', 'TT3 is impaired . Peripheral thyroid imbalances may arise from nutrient deficiencies , heavy metal exposure , adrenal stress , enzyme deficiencies , and chronic illnesses . ELEVATED REVERSE', 'TT3 LEVEL : A high or high normal rT3 level may inhibit the action of', 'TT3 Elevated rT3 may therefore lead to symptoms of hypothyroidism even if levels of', 'TSH', 'TT4 &', 'TT3 are adequate . Treatment Considerations : Consider', 'TT3 therapy Assess and treat iron , selenium , iodine and zinc THYROID AUTO - Abs THYROID PEROXIDASE Ab . 9.0 0.0 - 35.0 [ U / mL e pS ANTITHYROGLOBULIN Ab . 12.9 0.0 - 115 [ U / mL @ ||', 'TSH RECEPTOR AB 0.8 0.0 - 1.8 Tests ordered : TSHA ,', 'ESR', 'HBA1C INSF ,', 'LDH MG , PHOS , URAT , FBE , IS , FATS , LFT , FGLU , LIP , UEC , TFA , ITTCOM , Corca Pro ,', 'EGFR UECom , GLUCom , IMPEI , GHBCOM , VITD THAB , CFee , HOMA ( “ ) Result outside normal reference range ( H ) Result is above upper limit of reference rang ( L ) Result is below lower limit of reference range']\n",
      "Extracted results: [{'parameter': 'ESR', 'value': '20', 'unit': 'mm'}, {'parameter': 'ESR', 'value': '150', 'unit': 'g'}, {'parameter': 'EGFR', 'value': '90', 'unit': 'ml'}, {'parameter': 'EGFR', 'value': '90', 'unit': 'ml'}, {'parameter': 'AST', 'value': '80', 'unit': 'g'}, {'parameter': 'AST', 'value': '48', 'unit': 'g'}, {'parameter': 'AST', 'value': '39', 'unit': 'g'}, {'parameter': 'AST', 'value': '110', 'unit': 'mm'}, {'parameter': 'LDH', 'value': '35', 'unit': 'g'}]\n",
      "Processing file: ./files/data_0ca602c0-d93a-4ae2-b91f-532db7e174ae.csv\n",
      "Concatenated strings: 18/01/2024 _ Labref   ggggggggggg Coliecttime gggggggg   Yourref ggggggggg Reported 18/01/202X 05:13 PM Tests requested SOM , HOR , AND , PROLAC , COR , MBA Clinica . notes ~ Ce Se ee ee a ne eee INSULIN - LIKE GROWTH FACTOR-1 ( IGF1 ) Specimen Type : Serum IGF1 ( Somatomedin C ) 37 nmol / L ( 10 - 32 ) Insulin - like growth factor 1 ( IGF1 ) and insulin - like growth factor - binding protein 3 ( IGFBP3 ) measurements can be used to assess growth hormone ( GH ) excess or deficiency . For all applications , IGF1 measurement has generally been shown to have superior diagnostic accuracy . In particular , for the diagnosis and follow - up of acromegaly and gigantism , IGFBP3 measurement adds little extra diagnostic information . Elevated IGF1 levels support the diagnosis of acromegaly or gigantism in individuals with appropriate symptoms or signs . In successfully treated patients , levels should be within the reference interval , ideally within the lower third . SERUM HORMONE PROFILE Specimen Type : Serum Request Date FSH LUZHOR PROG E2(ATEL ) E2(BECK ) LUZHOR / FSH Number Collected IU / L = IU / L nmol / L pmol / L pmol / L Ratio 26777050 18 Jan 24 < 1 < 0.1 < 1 296 Reference Ranges FSH LUZHOR PROG E2(ATEL ) Males < 60 yrs < 7 < 7 0.9 - 3.9 < 150 > 60 yrs < 14 < 11 0.9 - 3.9 < 150 PLEASE NOTE : ' ESTR2 ( ATEL ) ' - ESTR2 by Siemens Atellica assay ' ESTR2 ( BECK ) ' - ESTR2 by Beckman Access assay SERUM ANDROGENS Total ANDRO ( Siemens ) 39.2 nmol / L ( 8.3 - 29 ) Sex Hormone Binding Globulin 34 nmol / t ( 11 - 71 ) DHEAS 4.4   umol / L ( 3.0 - 10 ) Calculated Free ANDRO 977.4 pmol / L ( 255.0 - 725.0 ) 1 of 2 M ORCPA , WwW SURGERY USE ars eta Na+ Pw ta OA Uy Wy \" + INTELUGENT , SCREENING IMTELLIGENT . SCREEMING Pathology Report — Resutts ENQUIRIES 2 er \" ree “ 7 G ww te Ch , Ot t3 ° 8 Ch Ire removed MS4/ 2919\n",
      "Regex pattern: (\\b(?:11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|Al|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|As|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|Br-|CRP|Cd2+|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|Cl-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|Cu2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|hs-cTnI|HIST|HCYS|IGC|IGC%|IPF|IRF|igA|igD|igE|igG|igM|BILIIN|IGF1|I2|Fe3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|Pb2+|LEP|LAP|LPSE|LPPA|Li+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|Mg2+|Mn2+|MCH|MCHC|MCV|MPV|MELAT|Hg2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCs|OXYT|PCPP|PTH|pCO2|pO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-He|RETI|RR%|SRNE|Na+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|vitA|vitB1|vitB12|vitB2|vitB3|vitB5|vitB6|vitB9|vitC|vitD|vitE|vitK1|WBC|Zn2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAb|TgAb|11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|AL|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|AS|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|BR-|CRP|CD2+|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CL-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|CU2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|HS-CTNI|HIST|HCYS|IGC|IGC%|IPF|IRF|IGA|IGD|IGE|IGG|IGM|BILIIN|IGF1|I2|FE3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|PB2+|LEP|LAP|LPSE|LPPA|LI+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|MG2+|MN2+|MCH|MCHC|MCV|MPV|MELAT|HG2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCS|OXYT|PCPP|PTH|PCO2|PO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-HE|RETI|RR%|SRNE|NA+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|VITA|VITB1|VITB12|VITB2|VITB3|VITB5|VITB6|VITB9|VITC|VITD|VITE|VITK1|WBC|ZN2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAB|TGAB)\\b)[\\s,:.]+\n",
      "Tokens: ['18/01/2024 _ Labref   ggggggggggg Coliecttime gggggggg   Yourref ggggggggg Reported 18/01/202X 05:13 PM Tests requested SOM , HOR , AND ,', 'PROLAC', 'COR , MBA Clinica . notes ~ Ce Se ee ee a ne eee INSULIN - LIKE GROWTH FACTOR-1 (', 'IGF1', ') Specimen Type : Serum', 'IGF1', '( Somatomedin C ) 37 nmol / L ( 10 - 32 ) Insulin - like growth factor 1 (', 'IGF1', ') and insulin - like growth factor - binding protein 3 ( IGFBP3 ) measurements can be used to assess growth hormone ( GH ) excess or deficiency . For all applications ,', 'IGF1', 'measurement has generally been shown to have superior diagnostic accuracy . In particular , for the diagnosis and follow - up of acromegaly and gigantism , IGFBP3 measurement adds little extra diagnostic information . Elevated', 'IGF1', 'levels support the diagnosis of acromegaly or gigantism in individuals with appropriate symptoms or signs . In successfully treated patients , levels should be within the reference interval , ideally within the lower third . SERUM HORMONE PROFILE Specimen Type : Serum Request Date', 'FSH', 'LUZHOR', 'PROG E2(ATEL ) E2(BECK )', 'LUZHOR', '/', 'FSH', 'Number Collected IU / L = IU / L nmol / L pmol / L pmol / L Ratio 26777050 18 Jan 24 < 1 < 0.1 < 1 296 Reference Ranges', 'FSH', 'LUZHOR', \"PROG E2(ATEL ) Males < 60 yrs < 7 < 7 0.9 - 3.9 < 150 > 60 yrs < 14 < 11 0.9 - 3.9 < 150 PLEASE NOTE : '\", 'ESTR2', \"( ATEL ) ' -\", 'ESTR2', \"by Siemens Atellica assay '\", 'ESTR2', \"( BECK ) ' -\", 'ESTR2', 'by Beckman Access assay SERUM ANDROGENS Total', 'ANDRO', '( Siemens ) 39.2 nmol / L ( 8.3 - 29 ) Sex Hormone Binding Globulin 34 nmol / t ( 11 - 71 )', 'DHEAS', '4.4   umol / L ( 3.0 - 10 ) Calculated Free', 'ANDRO', '977.4 pmol / L ( 255.0 - 725.0 ) 1 of 2 M ORCPA , WwW SURGERY USE ars eta Na+ Pw ta OA Uy Wy \" + INTELUGENT , SCREENING IMTELLIGENT . SCREEMING Pathology Report — Resutts ENQUIRIES 2 er \" ree “ 7 G ww te Ch , Ot t3 ° 8 Ch Ire removed MS4/ 2919']\n",
      "Combined tokens: ['18/01/2024 _ Labref   ggggggggggg Coliecttime gggggggg   Yourref ggggggggg Reported 18/01/202X 05:13 PM Tests requested SOM , HOR , AND ,', 'PROLAC COR , MBA Clinica . notes ~ Ce Se ee ee a ne eee INSULIN - LIKE GROWTH FACTOR-1 (', 'IGF1 ) Specimen Type : Serum', 'IGF1 ( Somatomedin C ) 37 nmol / L ( 10 - 32 ) Insulin - like growth factor 1 (', 'IGF1 ) and insulin - like growth factor - binding protein 3 ( IGFBP3 ) measurements can be used to assess growth hormone ( GH ) excess or deficiency . For all applications ,', 'IGF1 measurement has generally been shown to have superior diagnostic accuracy . In particular , for the diagnosis and follow - up of acromegaly and gigantism , IGFBP3 measurement adds little extra diagnostic information . Elevated', 'IGF1 levels support the diagnosis of acromegaly or gigantism in individuals with appropriate symptoms or signs . In successfully treated patients , levels should be within the reference interval , ideally within the lower third . SERUM HORMONE PROFILE Specimen Type : Serum Request Date', 'FSH', 'LUZHOR PROG E2(ATEL ) E2(BECK )', 'LUZHOR /', 'FSH Number Collected IU / L = IU / L nmol / L pmol / L pmol / L Ratio 26777050 18 Jan 24 < 1 < 0.1 < 1 296 Reference Ranges', 'FSH', \"LUZHOR PROG E2(ATEL ) Males < 60 yrs < 7 < 7 0.9 - 3.9 < 150 > 60 yrs < 14 < 11 0.9 - 3.9 < 150 PLEASE NOTE : '\", \"ESTR2 ( ATEL ) ' -\", \"ESTR2 by Siemens Atellica assay '\", \"ESTR2 ( BECK ) ' -\", 'ESTR2 by Beckman Access assay SERUM ANDROGENS Total', 'ANDRO ( Siemens ) 39.2 nmol / L ( 8.3 - 29 ) Sex Hormone Binding Globulin 34 nmol / t ( 11 - 71 )', 'DHEAS 4.4   umol / L ( 3.0 - 10 ) Calculated Free', 'ANDRO 977.4 pmol / L ( 255.0 - 725.0 ) 1 of 2 M ORCPA , WwW SURGERY USE ars eta Na+ Pw ta OA Uy Wy \" + INTELUGENT , SCREENING IMTELLIGENT . SCREEMING Pathology Report — Resutts ENQUIRIES 2 er \" ree “ 7 G ww te Ch , Ot t3 ° 8 Ch Ire removed MS4/ 2919']\n",
      "Extracted results: [{'parameter': 'ANDRO', 'value': '2', 'unit': 'm'}, {'parameter': 'ANDRO', 'value': '7', 'unit': 'g'}]\n",
      "Processing file: ./files/data_0deee5f5-f9d3-4712-8d2e-c5f7cd9895dc.csv\n",
      "Concatenated strings: 02/04/2019 ; Coll . Time : 17:30 Request No : 4499603 Ref . Range Units AMY 75 ( 25 - 120 ) U / L Lipase 203 ( 70 - 390 ) U / L AMY test performed on Siemens Advia / Attelica analyser Lipase test performed on Siemens Dimension analyser LFT - R , ECU - R , FBE - R , UMC - R , LSE - R , AML - R CC Drs : WEGMAN . Page : 2 of 3 MS HARLOT AMYLASE RUM All Tests Complete _ — - _ — _ — . ee a — ) , o~ a 7 es AUSTRALIAN LABORATORY 3427 - 18703 Referred : 02/04/19 removed removed removed 15:55 removed removed \\ removed 2022 Ph :   Sex : Female Clinical Notes : MICROBIOLOGY SPECIMEN : Mid Stream Urine + CHEMISTRY - PH : 7.0 Protein : Nil Glucose : Nil Blood : Nil . MICROSCOPY = * Leucocytes 75 x 10 ° /L ( < 10 ) RBC < 10 x 10 ° /L ( < 10 ) < Epithelial Cells + + a CULTURE No significant growth . om > @ @ | 2 e LFT - R , ECU - R , FBE - R , UMC - R , LSE - R , AML - R P5+ CC Drs : WEGMAN . Page : 3 of 3 Mi TAP LOT AMYLASE , SE All Tests Complete “ ut emnrn to gem 87 “ a wa a , al a ee , a ae te rT ane [ il ante oe a , ee a ie a “ Pr OMA ot Wa } i ; on ie AUSTRALIAN LABORATORY 3427 - 3420 Referred : 27/03/19 @Clinicalabs wav PT Oa : Byes Tel:1300 134 111 Printed : 04/04/19 15:57 Batch : 13054 1 removed \\ removed 2022 Ph :   Sex : Female Clinical Notes : SEROLOGY t CALPROTECTIN SPECIMEN : FAECES , Calprotectin 49 ug / g ( < 50 ) Interpretative Guide : Normal : < 50 ug / g 7 Mild inflammation : 51 - 200 ug / g Active inflammation : > 200 ug / g This test is performed using the DiaSorin Liaison XL Calprotectin assay . IMMUNOLOGY SPECIMEN : SERUM ds - DNA ANTIBODIES ( ELiA assay ) < 10 IU / mL ( < 10 ) ( Equivocal : 10 - 15 ) As of\n",
      "Regex pattern: (\\b(?:11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|Al|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|As|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|Br-|CRP|Cd2+|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|Cl-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|Cu2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|hs-cTnI|HIST|HCYS|IGC|IGC%|IPF|IRF|igA|igD|igE|igG|igM|BILIIN|IGF1|I2|Fe3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|Pb2+|LEP|LAP|LPSE|LPPA|Li+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|Mg2+|Mn2+|MCH|MCHC|MCV|MPV|MELAT|Hg2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCs|OXYT|PCPP|PTH|pCO2|pO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-He|RETI|RR%|SRNE|Na+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|vitA|vitB1|vitB12|vitB2|vitB3|vitB5|vitB6|vitB9|vitC|vitD|vitE|vitK1|WBC|Zn2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAb|TgAb|11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|AL|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|AS|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|BR-|CRP|CD2+|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CL-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|CU2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|HS-CTNI|HIST|HCYS|IGC|IGC%|IPF|IRF|IGA|IGD|IGE|IGG|IGM|BILIIN|IGF1|I2|FE3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|PB2+|LEP|LAP|LPSE|LPPA|LI+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|MG2+|MN2+|MCH|MCHC|MCV|MPV|MELAT|HG2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCS|OXYT|PCPP|PTH|PCO2|PO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-HE|RETI|RR%|SRNE|NA+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|VITA|VITB1|VITB12|VITB2|VITB3|VITB5|VITB6|VITB9|VITC|VITD|VITE|VITK1|WBC|ZN2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAB|TGAB)\\b)[\\s,:.]+\n",
      "Tokens: ['02/04/2019 ; Coll . Time : 17:30 Request No : 4499603 Ref . Range Units', 'AMY', '75 ( 25 - 120 ) U / L Lipase 203 ( 70 - 390 ) U / L', 'AMY', 'test performed on Siemens Advia / Attelica analyser Lipase test performed on Siemens Dimension analyser LFT - R , ECU - R , FBE - R , UMC - R , LSE - R , AML - R CC Drs : WEGMAN . Page : 2 of 3 MS HARLOT AMYLASE RUM All Tests Complete _ — - _ — _ — . ee a — ) , o~ a 7 es AUSTRALIAN LABORATORY 3427 - 18703 Referred : 02/04/19 removed removed removed 15:55 removed removed \\\\ removed 2022 Ph :   Sex : Female Clinical Notes : MICROBIOLOGY SPECIMEN : Mid Stream Urine + CHEMISTRY -', 'PH', '7.0 Protein : Nil Glucose : Nil Blood : Nil . MICROSCOPY = * Leucocytes 75 x 10 ° /L ( < 10 )', 'RBC', '< 10 x 10 ° /L ( < 10 ) < Epithelial Cells + + a CULTURE No significant growth . om > @ @ | 2 e LFT - R , ECU - R , FBE - R , UMC - R , LSE - R , AML - R P5+ CC Drs : WEGMAN . Page : 3 of 3 Mi TAP LOT AMYLASE , SE All Tests Complete “ ut emnrn to gem 87 “ a wa a , al a ee , a ae te rT ane [ il ante oe a , ee a ie a “ Pr OMA ot Wa } i ; on ie AUSTRALIAN LABORATORY 3427 - 3420 Referred : 27/03/19 @Clinicalabs wav PT Oa : Byes Tel:1300 134 111 Printed : 04/04/19 15:57 Batch : 13054 1 removed \\\\ removed 2022 Ph :   Sex : Female Clinical Notes : SEROLOGY t CALPROTECTIN SPECIMEN : FAECES , Calprotectin 49 ug / g ( < 50 ) Interpretative Guide : Normal : < 50 ug / g 7 Mild inflammation : 51 - 200 ug / g Active inflammation : > 200 ug / g This test is performed using the DiaSorin Liaison XL Calprotectin assay . IMMUNOLOGY SPECIMEN : SERUM ds - DNA ANTIBODIES ( ELiA assay ) < 10 IU / mL ( < 10 ) ( Equivocal : 10 - 15 )', 'As', 'of']\n",
      "Combined tokens: ['02/04/2019 ; Coll . Time : 17:30 Request No : 4499603 Ref . Range Units', 'AMY 75 ( 25 - 120 ) U / L Lipase 203 ( 70 - 390 ) U / L', 'AMY test performed on Siemens Advia / Attelica analyser Lipase test performed on Siemens Dimension analyser LFT - R , ECU - R , FBE - R , UMC - R , LSE - R , AML - R CC Drs : WEGMAN . Page : 2 of 3 MS HARLOT AMYLASE RUM All Tests Complete _ — - _ — _ — . ee a — ) , o~ a 7 es AUSTRALIAN LABORATORY 3427 - 18703 Referred : 02/04/19 removed removed removed 15:55 removed removed \\\\ removed 2022 Ph :   Sex : Female Clinical Notes : MICROBIOLOGY SPECIMEN : Mid Stream Urine + CHEMISTRY -', 'PH 7.0 Protein : Nil Glucose : Nil Blood : Nil . MICROSCOPY = * Leucocytes 75 x 10 ° /L ( < 10 )', 'RBC < 10 x 10 ° /L ( < 10 ) < Epithelial Cells + + a CULTURE No significant growth . om > @ @ | 2 e LFT - R , ECU - R , FBE - R , UMC - R , LSE - R , AML - R P5+ CC Drs : WEGMAN . Page : 3 of 3 Mi TAP LOT AMYLASE , SE All Tests Complete “ ut emnrn to gem 87 “ a wa a , al a ee , a ae te rT ane [ il ante oe a , ee a ie a “ Pr OMA ot Wa } i ; on ie AUSTRALIAN LABORATORY 3427 - 3420 Referred : 27/03/19 @Clinicalabs wav PT Oa : Byes Tel:1300 134 111 Printed : 04/04/19 15:57 Batch : 13054 1 removed \\\\ removed 2022 Ph :   Sex : Female Clinical Notes : SEROLOGY t CALPROTECTIN SPECIMEN : FAECES , Calprotectin 49 ug / g ( < 50 ) Interpretative Guide : Normal : < 50 ug / g 7 Mild inflammation : 51 - 200 ug / g Active inflammation : > 200 ug / g This test is performed using the DiaSorin Liaison XL Calprotectin assay . IMMUNOLOGY SPECIMEN : SERUM ds - DNA ANTIBODIES ( ELiA assay ) < 10 IU / mL ( < 10 ) ( Equivocal : 10 - 15 )', 'As of']\n",
      "Extracted results: [{'parameter': 'PH', 'value': '10', 'unit': '°'}, {'parameter': 'RBC', 'value': '10', 'unit': '°'}, {'parameter': 'RBC', 'value': '3', 'unit': 'mi'}]\n",
      "Processing file: ./files/data_0c59298d-4205-4f6a-8bc9-c078123da03a.csv\n",
      "Concatenated strings: 18/01/2024 05:13 PM Tests requested SOM , HOR , AND , PROLAC , COR , MBA Clinical notes INSULIN - LIKE GROWTH FACTOR-1 ( IGF1 ) Specimen Type : Serum IGF1 ( Somatomedin C ) 37 nmol / L ( 10 - 32 ) Insulin - like growth factor 1 ( IGF1 ) and insulin - like growth factor - binding protein 3 ( IGFBP3 ) measurements can be used to assess growth hormone ( GH ) excess or deficiency . For all applications , IGF1 measurement has generally been shown to have superior diagnostic accuracy . In particular , for the diagnosis and follow - up of acromegaly and gigantism , IGFBP3 measurement adds little extra diagnostic information . Elevated IGF1 levels support the diagnosis of acromegaly or gigantism in individuals with appropriate symptoms or signs . In successfully treated patients , levels should be within the reference interval , ideally within the lower third . SERUM HORMONE PROFILE Specimen Type : Serum Request Date FSH LUZHOR PROG E2(ATEL ) E2(BECK ) LUZHOR / FSH Number Collected IU / L IU / L nmol / L pmol / L pmol / L Ratio 26777050 18 Jan 24 < 1 < 0.1 < 1 296 Reference Ranges FSH LUZHOR PROG E2(ATEL ) Males < 60 yrs < 7 < 7 0.9 - 3.9 < 150 > 60 yrs < 14 < 11 0.9 - 3.9 < 150 PLEASE NOTE : ' ESTR2 ( ATEL ) ' - ESTR2 by Siemens Atellica assay ' ESTR2 ( BECK ) ' - ESTR2 by Beckman Access assay SURGERY USE SERUM ANDROGENS Normal Total ANDRO ( Siemens ) 39.2 nmol / L ( 8.3 - 29 ) Sex Hormone Binding Globulin 34 nmol / L ( 11 - 71 ) No ActionFile DHEAS 4.4   umol / L ( 3.0 - 10 ) | Calculated Free ANDRO 977.4 pmol / L ( 255.0 - 725.0 ) nen Make Appoint . Further Tests Notes Required Speak with Dr 1 of ? On Correct Treatment LAV_RTE001_AV3_07/23 hl laverty Pathology Report Resutts ORCPA mm ENQUIRIES Accredited for compliance win » WA pathology NPAAC Standards and ISO 15189 pon RE ans ei removed removed removed removed Phone D.O.B XXXXXXXXXXX Mm removed Reported\n",
      "Regex pattern: (\\b(?:11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|Al|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|As|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|Br-|CRP|Cd2+|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|Cl-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|Cu2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|hs-cTnI|HIST|HCYS|IGC|IGC%|IPF|IRF|igA|igD|igE|igG|igM|BILIIN|IGF1|I2|Fe3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|Pb2+|LEP|LAP|LPSE|LPPA|Li+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|Mg2+|Mn2+|MCH|MCHC|MCV|MPV|MELAT|Hg2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCs|OXYT|PCPP|PTH|pCO2|pO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-He|RETI|RR%|SRNE|Na+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|vitA|vitB1|vitB12|vitB2|vitB3|vitB5|vitB6|vitB9|vitC|vitD|vitE|vitK1|WBC|Zn2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAb|TgAb|11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|AL|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|AS|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|BR-|CRP|CD2+|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CL-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|CU2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|HS-CTNI|HIST|HCYS|IGC|IGC%|IPF|IRF|IGA|IGD|IGE|IGG|IGM|BILIIN|IGF1|I2|FE3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|PB2+|LEP|LAP|LPSE|LPPA|LI+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|MG2+|MN2+|MCH|MCHC|MCV|MPV|MELAT|HG2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCS|OXYT|PCPP|PTH|PCO2|PO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-HE|RETI|RR%|SRNE|NA+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|VITA|VITB1|VITB12|VITB2|VITB3|VITB5|VITB6|VITB9|VITC|VITD|VITE|VITK1|WBC|ZN2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAB|TGAB)\\b)[\\s,:.]+\n",
      "Tokens: ['18/01/2024 05:13 PM Tests requested SOM , HOR , AND ,', 'PROLAC', 'COR , MBA Clinical notes INSULIN - LIKE GROWTH FACTOR-1 (', 'IGF1', ') Specimen Type : Serum', 'IGF1', '( Somatomedin C ) 37 nmol / L ( 10 - 32 ) Insulin - like growth factor 1 (', 'IGF1', ') and insulin - like growth factor - binding protein 3 ( IGFBP3 ) measurements can be used to assess growth hormone ( GH ) excess or deficiency . For all applications ,', 'IGF1', 'measurement has generally been shown to have superior diagnostic accuracy . In particular , for the diagnosis and follow - up of acromegaly and gigantism , IGFBP3 measurement adds little extra diagnostic information . Elevated', 'IGF1', 'levels support the diagnosis of acromegaly or gigantism in individuals with appropriate symptoms or signs . In successfully treated patients , levels should be within the reference interval , ideally within the lower third . SERUM HORMONE PROFILE Specimen Type : Serum Request Date', 'FSH', 'LUZHOR', 'PROG E2(ATEL ) E2(BECK )', 'LUZHOR', '/', 'FSH', 'Number Collected IU / L IU / L nmol / L pmol / L pmol / L Ratio 26777050 18 Jan 24 < 1 < 0.1 < 1 296 Reference Ranges', 'FSH', 'LUZHOR', \"PROG E2(ATEL ) Males < 60 yrs < 7 < 7 0.9 - 3.9 < 150 > 60 yrs < 14 < 11 0.9 - 3.9 < 150 PLEASE NOTE : '\", 'ESTR2', \"( ATEL ) ' -\", 'ESTR2', \"by Siemens Atellica assay '\", 'ESTR2', \"( BECK ) ' -\", 'ESTR2', 'by Beckman Access assay SURGERY USE SERUM ANDROGENS Normal Total', 'ANDRO', '( Siemens ) 39.2 nmol / L ( 8.3 - 29 ) Sex Hormone Binding Globulin 34 nmol / L ( 11 - 71 ) No ActionFile', 'DHEAS', '4.4   umol / L ( 3.0 - 10 ) | Calculated Free', 'ANDRO', '977.4 pmol / L ( 255.0 - 725.0 ) nen Make Appoint . Further Tests Notes Required Speak with Dr 1 of ? On Correct Treatment LAV_RTE001_AV3_07/23 hl laverty Pathology Report Resutts ORCPA mm ENQUIRIES Accredited for compliance win » WA pathology NPAAC Standards and ISO 15189 pon RE ans ei removed removed removed removed Phone D.O.B XXXXXXXXXXX Mm removed Reported']\n",
      "Combined tokens: ['18/01/2024 05:13 PM Tests requested SOM , HOR , AND ,', 'PROLAC COR , MBA Clinical notes INSULIN - LIKE GROWTH FACTOR-1 (', 'IGF1 ) Specimen Type : Serum', 'IGF1 ( Somatomedin C ) 37 nmol / L ( 10 - 32 ) Insulin - like growth factor 1 (', 'IGF1 ) and insulin - like growth factor - binding protein 3 ( IGFBP3 ) measurements can be used to assess growth hormone ( GH ) excess or deficiency . For all applications ,', 'IGF1 measurement has generally been shown to have superior diagnostic accuracy . In particular , for the diagnosis and follow - up of acromegaly and gigantism , IGFBP3 measurement adds little extra diagnostic information . Elevated', 'IGF1 levels support the diagnosis of acromegaly or gigantism in individuals with appropriate symptoms or signs . In successfully treated patients , levels should be within the reference interval , ideally within the lower third . SERUM HORMONE PROFILE Specimen Type : Serum Request Date', 'FSH', 'LUZHOR PROG E2(ATEL ) E2(BECK )', 'LUZHOR /', 'FSH Number Collected IU / L IU / L nmol / L pmol / L pmol / L Ratio 26777050 18 Jan 24 < 1 < 0.1 < 1 296 Reference Ranges', 'FSH', \"LUZHOR PROG E2(ATEL ) Males < 60 yrs < 7 < 7 0.9 - 3.9 < 150 > 60 yrs < 14 < 11 0.9 - 3.9 < 150 PLEASE NOTE : '\", \"ESTR2 ( ATEL ) ' -\", \"ESTR2 by Siemens Atellica assay '\", \"ESTR2 ( BECK ) ' -\", 'ESTR2 by Beckman Access assay SURGERY USE SERUM ANDROGENS Normal Total', 'ANDRO ( Siemens ) 39.2 nmol / L ( 8.3 - 29 ) Sex Hormone Binding Globulin 34 nmol / L ( 11 - 71 ) No ActionFile', 'DHEAS 4.4   umol / L ( 3.0 - 10 ) | Calculated Free', 'ANDRO 977.4 pmol / L ( 255.0 - 725.0 ) nen Make Appoint . Further Tests Notes Required Speak with Dr 1 of ? On Correct Treatment LAV_RTE001_AV3_07/23 hl laverty Pathology Report Resutts ORCPA mm ENQUIRIES Accredited for compliance win » WA pathology NPAAC Standards and ISO 15189 pon RE ans ei removed removed removed removed Phone D.O.B XXXXXXXXXXX Mm removed Reported']\n",
      "Extracted results: []\n",
      "Processing file: ./files/data_0ab9800e-bc9a-4388-aaa2-d4fc05e7d111.csv\n",
      "Concatenated strings: 10/12/2018 Date Collected :\n",
      "Regex pattern: (\\b(?:11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|Al|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|As|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|Br-|CRP|Cd2+|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|Ca2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|Cl-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|Cu2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|hs-cTnI|HIST|HCYS|IGC|IGC%|IPF|IRF|igA|igD|igE|igG|igM|BILIIN|IGF1|I2|Fe3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|Pb2+|LEP|LAP|LPSE|LPPA|Li+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|Mg2+|Mn2+|MCH|MCHC|MCV|MPV|MELAT|Hg2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCs|OXYT|PCPP|PTH|pCO2|pO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-He|RETI|RR%|SRNE|Na+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|vitA|vitB1|vitB12|vitB2|vitB3|vitB5|vitB6|vitB9|vitC|vitD|vitE|vitK1|WBC|Zn2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAb|TgAb|11DEOXY|17OHP|ACACT|ALT|ALB|AL/GLO|ALD|ALP|AAT1|AATD|AFP|A2MACR|AABA|HBDH|A1GLO|A2GLO|AL|NH3|ANDRO|ANSTED|ACE|ANGAP|ADH|ARG|AS|AST|BNP|BASO|BASO%|B2M|BGLO|BHYD|HCO3|BLT|FXIV|O2SAT|BUN|BR-|CRP|CD2+|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CCTN|CA2+|CA125|CA2729|CA199|CA153|CO2|HBCO|CEA|CRPLN|CL-|CHOL/HDL|CCK|CHLN|CGA|C1Q|C1EI|C2|C3|C4|C5|C6|BILIC|CU2+|CORT|CREAN|CK|CKMB|CREA|CGMP|CYS|DHEA|DHEAS|DHTT|EGFR|EOS|EOSINO%|ESR|EPOE|ESTR2|ESTR1|F5|INSLN|FERR|FIBR|FSH|FPSA|FT3|FT4|FRUCT|GALT|GGLO|GGT|GTRN|GLOB|GLCGN|GLUC|G6PD|GLCRL|GLYCC|HPTGB|HBA1C|HDLC|HCT|HGB|HS-CTNI|HIST|HCYS|IGC|IGC%|IPF|IRF|IGA|IGD|IGE|IGG|IGM|BILIIN|IGF1|I2|FE3+|UIBC|ILEL|LDH|LACTL|LACPYR|LDLC|PB2+|LEP|LAP|LPSE|LPPA|LI+|LZH|LUZHOR|LYMPH|LYMPHO%|LYSK|MURA|MIP1A|MIP1B|MPLC|MG2+|MN2+|MCH|MCHC|MCV|MPV|MELAT|HG2+|METHHGB|METM|MONO|MONO%|MYOGLOB|NGF|NEUT|NEUTRO%|NONHDL|NRBCS|OXYT|PCPP|PTH|PCO2|PO2|PTPT|PH|PHEALA|PHETYR|P5+|PLAT|PDGF|K+|PROGST|PROLAC|PSA|PTT|RBC|RDW|RENI|RET-HE|RETI|RR%|SRNE|NA+|SCCC|TESTO|THRT|THYGL|TSH|TT4|BILIT|CHOL|MPSWB|PROT|TFER|TFESAT|TRIGL|TT3|TROPI|TROPT|URIC|VALI|VLDLC|VITA|VITB1|VITB12|VITB2|VITB3|VITB5|VITB6|VITB9|VITC|VITD|VITE|VITK1|WBC|ZN2+|FGLUC|ANTIDNA_AB_RIA|ANA|ANCA_SCREEN|SS_A_60|SS_B|RO_52|SCL_70|JO_1|CENP_B|SM_AB|RNP_AB|RIBO_P_AB|CMV_IGG|CMV_IGM|MUM_IGG|MEAS_IGG|RHEUM_FAC|CCP_ABS|TOX_IGG|TOX_IGM|UREA|PO4|PCV|A/G_RATIO|AMY|PDW|TFT-R|TFT|TPOAB|TGAB)\\b)[\\s,:.]+\n",
      "Tokens: ['10/12/2018 Date Collected :']\n",
      "Combined tokens: ['10/12/2018 Date Collected :']\n",
      "Extracted results: []\n"
     ]
    }
   ],
   "source": [
    "import glob\n",
    "import pandas as pd\n",
    "import json\n",
    "import re\n",
    "\n",
    "def process_records(csv_file, FILE_NAME):\n",
    "    print(f\"Processing file: {csv_file}\")\n",
    "    # Read the CSV file into a DataFrame\n",
    "    df = pd.read_csv(csv_file)\n",
    "    \n",
    "    # Replace 'token' column with 'Abbreviations' where 'Abbreviations' is not NaN\n",
    "    abbr_df = df.copy()\n",
    "    abbr_df['token'] = abbr_df.apply(lambda row: row['Abbreviation'] if pd.notnull(row['Abbreviation']) else row['token'], axis=1)\n",
    "    abbr_df.drop(columns=['Abbreviation'], inplace=True)\n",
    "    \n",
    "    # Load the JSON file\n",
    "    with open('X1.json', 'r') as file:\n",
    "        data = json.load(file)\n",
    "    \n",
    "    # Extract values of 'Abbreviation' from the JSON data\n",
    "    abbr_value_list = [item['Abbreviation'] for item in data if 'Abbreviation' in item]\n",
    "    \n",
    "    # Concatenate 'token' column values into a single string\n",
    "    concatenated_strings = \" \".join(abbr_df['token'].astype(str))\n",
    "    print(\"Concatenated strings:\", concatenated_strings)\n",
    "    \n",
    "    # Define a regex pattern for finding abbreviation matches\n",
    "    pattern = r'(\\b(?:' + '|'.join(abbr_value_list + [word.upper() for word in abbr_value_list]) + r')\\b)[\\s,:.]+'\n",
    "    print(\"Regex pattern:\", pattern)\n",
    "    \n",
    "    # Tokenize the original text based on the regex pattern\n",
    "    tokens = re.split(pattern, concatenated_strings)\n",
    "    tokens = [token.strip() for token in tokens if token.strip()]  # Remove empty tokens and strip leading/trailing whitespaces\n",
    "    print(\"Tokens:\", tokens)\n",
    "    \n",
    "    # Combine tokens into phrases\n",
    "    combined_tokens = []\n",
    "    i = 0\n",
    "    while i < len(tokens):\n",
    "        combined_token = tokens[i]\n",
    "        i += 1\n",
    "        while i < len(tokens) and tokens[i] not in abbr_value_list:\n",
    "            combined_token += ' ' + tokens[i]\n",
    "            i += 1\n",
    "        combined_tokens.append(combined_token)\n",
    "    print(\"Combined tokens:\", combined_tokens)\n",
    "    \n",
    "    # Extract parameter values from combined tokens\n",
    "    result = []\n",
    "    universal_units = [\n",
    "        \"mm\", \"cm\", \"m\", \"km\", \"mg\", \"g\", \"kg\", \"ml\", \"L\", \"°C\", \"°F\", \n",
    "        \"in\", \"ft\", \"yd\", \"mi\", \"M\", \"k\", \"°\", \"s\", \"Hz\", \"N\", \"Pa\", \"J\", \n",
    "        \"W\", \"C\", \"V\", \"F\", \"Ω\", \"S\", \"Wb\", \"T\", \"H\", \"lm\", \"lx\", \"Bq\", \n",
    "        \"Gy\", \"Sv\", \"kat\", \"mol\", \"dB\", \"rpm\", \"rad\", \"g/cm³\", \"m/s²\", \n",
    "        \"m²\", \"m³\", \"m/s\", \"m/s²\", \"m/s³\", \"m/s⁴\", \"m/s⁵\", \"m/s⁶\", \n",
    "        \"m²/s\", \"m²/s²\", \"m³/s\", \"m³/s²\", \"m³/s³\", \"m/s³\", \"N/m\", \"N/m²\", \n",
    "        \"N/m³\", \"Pa/s\", \"Pa/s²\", \"J/K\", \"J/mol\", \"J/(mol·K)\", \"J/kg\", \n",
    "        \"J/(kg·K)\", \"J/m\", \"J/m²\", \"J/m³\", \"W/m\", \"W/m²\", \"W/m³\", \"W/(m·K)\", \n",
    "        \"W/(m²·K)\", \"W/(m³·K)\", \"C/m³\", \"C/m²\", \"C/m\", \"V/m\", \"F/m\", \"Ω/m\", \n",
    "        \"S/m\", \"T/m\", \"H/m\", \"mol/m³\", \"kat/m³\", \"kg/m\", \"g/m\", \"mol/m²\", \n",
    "        \"mol/m³\", \"kat/m²\", \"kat/m³\", \"g/kmol\", \"g/mol\", \"g/m²\", \"g/m³\", \n",
    "        \"kg/kmol\", \"kg/mol\", \"kg/m²\", \"kg/m³\", \"L/mol\", \"L/m³\", \"lm/W\", \n",
    "        \"lx·s\", \"kat/kg\", \"kat/mg\", \"kat/g\", \"kat/kg\", \"kat/kg·s\", \"kat/mg·s\",\n",
    "        \"kat/g·s\", \"kat/kg·s\", \"m²/g\", \"m²/kg\", \"m²/mg\", \"m²/g·s\", \"m²/kg·s\",\n",
    "        \"m²/mg·s\", \"m³/g\", \"m³/kg\", \"m³/mg\", \"m³/g·s\", \"m³/kg·s\", \"m³/mg·s\",\n",
    "        \"m/s·g\", \"m/s·kg\", \"m/s·mg\", \"m/s·g·s\", \"m/s·kg·s\", \"m/s·mg·s\", \n",
    "        \"m/s²·g\", \"m/s²·kg\", \"m/s²·mg\", \"m/s²·g·s\", \"m/s²·kg·s\", \"m/s²·mg·s\",\n",
    "        \"N·s\", \"N/m²·s\", \"N/m³·s\", \"N·m\", \"N/m·s\", \"N/m²·s\", \"N/m³·s\", \"Pa·s\",\n",
    "        \"Pa·s²\", \"Pa/m\", \"Pa/m²\", \"Pa/m³\", \"Pa/m²·s\", \"J/m\", \"J/m²\", \"J/m³\", \n",
    "        \"J/kg·s\", \"J/m²·s\", \"J/m³·s\", \"W/m\", \"W/m²\", \"W/m³\", \"W/m²·K\", \"W/m³·K\", \n",
    "        \"W/m²·s\", \"W/m³·s\", \"C/m\", \"C/m²\", \"C/m³\", \"C/m²·s\", \"C/m³·s\", \"V/m\", \n",
    "        \"V/m²\", \"V/m³\", \"F/m\", \"F/m²\", \"F/m³\", \"Ω/m\", \"Ω/m²\", \"Ω/m³\", \"S/m\", \n",
    "        \"S/m²\", \"S/m³\", \"T/m\", \"T/m²\", \"T/m³\", \"H/m\", \"H/m²\", \"H/m³\", \"lm/m²\", \n",
    "        \"lx/m²\", \"Bq/m\", \"Bq/m²\", \"Bq/m³\", \"Gy/s\", \"Gy/m²\", \"Gy/m³\", \"Sv/s\", \n",
    "        \"Sv/m²\", \"Sv/m³\", \"kat/m\", \"kat/m²\", \"kat/m³\", \"mol/m\", \"mol/m²\", \n",
    "        \"mol/m³\", \"dB/m\", \"rpm/m\", \"rpm/m²\", \"rad/m\", \"rad/m²\", \"g/cm²\", \"g/cm³\", \n",
    "        \"kg/m²\", \"kg/m³\", \"g/m²\", \"g/m³\", \"mg/m²\", \"mg/m³\", \"kg/m²·s\", \"kg/m³·s\", \n",
    "        \"g/m²·s\", \"g/m³·s\", \"mg/m²·s\", \"mg/m³·s\", \"kg/m²·K\", \"kg/m³·K\", \"g/m²·K\", \n",
    "        \"g/m³·K\", \"mg/m²·K\", \"mg/m³·K\", \"kg/m²·s·K\", \"kg/m³·s·K\", \"g/m²·s·K\", \n",
    "        \"g/m³·s·K\", \"mg/m²·s·K\", \"mg/m³·s·K\"\n",
    "    ]\n",
    "\n",
    "    # Extract parameter values from combined tokens\n",
    "    for item in combined_tokens:\n",
    "        words = item.split()\n",
    "        for i, word in enumerate(words):\n",
    "            if word.lower() in universal_units:\n",
    "                if i > 0 and re.match(r'^\\d+(?:\\.\\d+)?$', words[i - 1]):\n",
    "                    value = words[i - 1]\n",
    "                    unit = word.lower()\n",
    "                    parameter = words[0]\n",
    "                    result.append({\"parameter\": parameter, \"value\": value, \"unit\": unit})\n",
    "    print(\"Extracted results:\", result)\n",
    "    \n",
    "    # Write the extracted results to a text file\n",
    "    with open(f\"./results/result_{FILE_NAME}.txt\", 'w') as file:\n",
    "        for item in result:\n",
    "            file.write(\"%s\\n\" % item)\n",
    "\n",
    "# Get the list of CSV files in the directory\n",
    "records = glob.glob('./files/*.csv')\n",
    "# Process each CSV file iteratively\n",
    "for file_path in records:\n",
    "    FILE_NAME = file_path.split(\"_\", 2)[1].split(\".\", 2)[0]\n",
    "    process_records(file_path, FILE_NAME)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "42fe8281",
   "metadata": {},
   "source": [
    "# Challenges and Hard Parts: `process_records` Function\n",
    "\n",
    "## Overview:\n",
    "The `process_records` function aims to parse CSV files, replace values, extract parameter values, and write the results to a text file. Despite its straightforward goal, several challenges and complexities were encountered during its implementation.\n",
    "\n",
    "## Challenges:\n",
    "\n",
    "1. **Data Parsing Complexity**:\n",
    "   - Parsing CSV files and handling DataFrame operations were challenging, especially with large datasets or complex data structures.\n",
    "\n",
    "2. **Abbreviation Matching**:\n",
    "   - Matching abbreviations from the 'Abbreviation' column to the 'token' column involved complexity in handling cases, punctuation, and variations in text format.\n",
    "\n",
    "3. **Regular Expression Complexity**:\n",
    "   - Constructing and debugging regular expressions for tokenization and abbreviation matching were complex, particularly when dealing with various text formats and patterns.\n",
    "\n",
    "4. **Data Integration**:\n",
    "   - Integrating data from different sources, such as CSV files and JSON files, required careful handling to ensure data consistency and accuracy.\n",
    "\n",
    "5. **Error Handling**:\n",
    "   - Handling errors gracefully, such as missing files or unexpected data formats, was crucial for robustness and reliability.\n",
    "\n",
    "## Hard Parts:\n",
    "\n",
    "1. **Optimizing Performance**:\n",
    "   - Ensuring the function's efficiency and scalability, especially with large datasets, required optimization techniques and careful resource management.\n",
    "\n",
    "2. **Handling Edge Cases**:\n",
    "   - Addressing edge cases and corner scenarios, such as rare abbreviations or irregular text patterns, posed challenges in ensuring comprehensive data processing.\n",
    "\n",
    "3. **Maintaining Code Readability**:\n",
    "   - Balancing between code complexity and readability was crucial for maintainability and collaboration, especially in a function with multiple processing steps and dependencies.\n",
    "\n",
    "4. **Testing and Validation**:\n",
    "   - Developing comprehensive test cases and validation methods to verify the accuracy and correctness of the function's output was essential but time-consuming.\n",
    "\n",
    "5. **Documentation and Communication**:\n",
    "   - Clearly documenting the function's behavior, parameters, and usage, as well as effectively communicating challenges and solutions to team members, stakeholders, or users, was vital for understanding and collaboration.\n",
    "\n",
    "## Conclusion:\n",
    "The `process_records` function involved several challenges and hard parts related to data parsing, text processing, error handling, performance optimization, and documentation. Addressing these challenges required a combination of technical expertise, problem-solving skills, and effective communication within the development team.\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4b2e97d2",
   "metadata": {},
   "source": [
    "# Results can be read here "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "5e5cf830",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[]\n",
      "[]\n",
      "[\"{'parameter': 'PH', 'value': '10', 'unit': '°'}\\n\", \"{'parameter': 'RBC', 'value': '10', 'unit': '°'}\\n\", \"{'parameter': 'RBC', 'value': '3', 'unit': 'mi'}\\n\"]\n",
      "[\"{'parameter': 'ANDRO', 'value': '2', 'unit': 'm'}\\n\", \"{'parameter': 'ANDRO', 'value': '7', 'unit': 'g'}\\n\"]\n",
      "[\"{'parameter': 'ESR', 'value': '20', 'unit': 'mm'}\\n\", \"{'parameter': 'ESR', 'value': '150', 'unit': 'g'}\\n\", \"{'parameter': 'EGFR', 'value': '90', 'unit': 'ml'}\\n\", \"{'parameter': 'EGFR', 'value': '90', 'unit': 'ml'}\\n\", \"{'parameter': 'AST', 'value': '80', 'unit': 'g'}\\n\", \"{'parameter': 'AST', 'value': '48', 'unit': 'g'}\\n\", \"{'parameter': 'AST', 'value': '39', 'unit': 'g'}\\n\", \"{'parameter': 'AST', 'value': '110', 'unit': 'mm'}\\n\", \"{'parameter': 'LDH', 'value': '35', 'unit': 'g'}\\n\"]\n",
      "[\"{'parameter': 'EGFR', 'value': '79', 'unit': 'ml'}\\n\"]\n",
      "[]\n",
      "[]\n",
      "[\"{'parameter': 'I2', 'value': '254.65', 'unit': 'mg'}\\n\"]\n"
     ]
    }
   ],
   "source": [
    "results = glob.glob('./results/*.txt')\n",
    "for i in results:\n",
    "    file = open(i, \"r\")\n",
    "    content=file.readlines()\n",
    "    print(content)\n",
    "    file.close()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
